

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/50, C12N 15/12, A61K 38/18		A2	(11) International Publication Number: WO 96/11949
			(43) International Publication Date: 25 April 1996 (25.04.96)
(21) International Application Number: PCT/IB95/00971		Suite 2105, 6400 Christie Avenue, Emeryville, CA 94608 (US). HSU, Eric, W. [US/US]; 2110 Mapleleaf Avenue, Thousand Oaks, CA 91320 (US). (74) Agents: ODRE, Steven, M. et al.; Amgen Inc., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US). (81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date: 12 October 1995 (12.10.95)			
(30) Priority Data: 08/323,340 13 October 1994 (13.10.94) US 08/323,475 13 October 1994 (13.10.94) US 08/487,825 7 June 1995 (07.06.95) US			
(60) Parent Applications or Grants (63) Related by Continuation US 08/323,340 (CIP) Filed on 13 October 1994 (13.10.94) US 08/487,825 (CIP) Filed on 7 June 1995 (07.06.95)			
(71) Applicant (for all designated States except US): AMGEN INC. [US/US]; Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MORRIS, Charles, F. [US/US]; 3393 Daniel Street, Newbury Park, CA 91320 (US). KENNEY, William, C. [US/US]; 2654 Castillo Circle, Thousand Oaks, CA 91360 (US). CHEN, Bao-Lu [US/US];		Published <i>Without international search report and to be republished upon receipt of that report.</i>	

(54) Title: ANALOGS OF KERATINOCYTE GROWTH FACTOR**(57) Abstract**

The present invention concerns polypeptide analogs of a potent mitogen of non-fibroblast epithelial cell growth, keratinocyte growth factor (KGF) having up to the first 24 N-terminal amino acids modified wherein cysteine residues corresponding to amino acid positions 1 and 15 of the KGF [amino acid positions 32 and 46 of SEQ ID No:2, (Cys¹ and Cys¹⁵, respectively)] are deleted or substituted with another amino acid. Also disclosed are nucleic acid molecules encoding such analogs, as well as methods for using such analogs to stimulate non-fibroblast epithelial cell proliferation.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

ANALOGS OF KERATINOCYTE GROWTH FACTOR

Field of the Invention

5 The present invention relates to recombinant
DNA technology and protein engineering. Specifically,
recombinant DNA methodologies have been applied to
generate polypeptide analogs of keratinocyte growth
factor (KGF), a potent mitogen of non-fibroblast
10 epithelial cell growth, wherein the analogs have
improved stability as compared to that of the parent
KGF.

Background of the Invention

15 The complex process of tissue generation and
regeneration is mediated by a number of protein factors
sometimes referred to as soft tissue growth factors.
These molecules are generally released by one cell type
20 and act to influence proliferation of other cell types.
(Rubin et al. (1989), *Proc. Nat'l. Acad. Sci. USA*,
86:802-806). Some soft tissue growth factors are
secreted by particular cell types and influence the
proliferation, differentiation, and/or maturation of
25 responsive cells in the development of multicellular
organisms (Finch et al. (1989), *Science*, 245:752-755).
In addition to their roles in developing organisms, some
are significant in the continued health and maintenance
of more mature systems. For instance, in mammals, there
30 are many systems where rapid cell turnover occurs. Such
systems include the skin and the gastrointestinal tract,
both of which are comprised of epithelial cells.
Included within this group of soft tissue growth factors
is a protein family of fibroblast growth factors (FGFs).
35 There are currently eight known FGF family
members which share a relatedness among primary

- 2 -

structures: basic fibroblast growth factor, bFGF (Abraham et al. (1986), *EMBO J.*, 5:2523-2528); acidic fibroblast growth factor, aFGF (Jaye et al. (1986), *Science*, 233:541-545); int-2 gene product, int-2
5 (Dickson & Peters (1987), *Nature*, 326:833); hst/kFGF (Delli-Bovi et al. (1987), *Cell*, 50:729-737) and Yoshida et al. (1987), *Proc. Natl. Acad. Sci. USA*, 84:7305-7309); FGF-5 (Zhan et al. (1988), *Mol. Cell. Biol.*, 8:3487-3495); FGF-6 (Marics et al. (1989), *Oncogene*,
10 4:335-340); keratinocyte growth factor (Finch et al. (1989), *Science*, 24:752-755); and hisactophilin (Habazzettl et al. (1992), *Nature*, 359:855-858).

Among the FGF family of proteins, keratinocyte growth factor ("KGF") is a unique effector of non-
15 fibroblast epithelial (particularly keratinocyte) cell proliferation derived from mesenchymal tissues. The term "native KGF" refers to a natural human (hKGF) or recombinant (rKGF) polypeptide (with or without a signal sequence) as depicted by the amino acid sequence
20 presented in SEQ ID NO:2 or an allelic variant thereof. [Unless otherwise indicated, amino acid numbering for molecules described herein shall correspond to that presented for the mature form of the native molecule (i.e., minus the signal sequence), as depicted by amino
25 acids 32 to 194 of SEQ ID NO:2.]

Native KGF may be isolated from natural human sources (hKGF) or produced by recombinant DNA techniques (rKGF) (Finch et al. (1989), *supra*; Rubin et al. (1989), *supra*; Ron et al. (1993), *The Journal of Biological*
30 *Chemistry*, 268(4):2984-2988; and Yan et al. (1991), *In Vitro Cell. Dev. Biol.*, 27A:437-438).

It is known that native KGF is relatively unstable in the aqueous state and that it undergoes chemical and physical degradation resulting in a loss
35 of biological activity during processing and storage (Chen et al. (1994), *Pharmaceutical Research*, 11:1582-

- 3 -

1589). Native KGF is prone also to aggregation at elevated temperatures and it becomes inactivated under acidic conditions (Rubin et al. (1989), *Proc. Natl. Acad. Sci. USA*, 86:802-806). Aggregation of native KGF in aqueous solution also results in inactivated protein. This is disadvantageous because such loss of activity makes it impractical to store aqueous formulations of native KGF proteins for extended periods of time or to administer the protein over extended periods. Moreover, this is particularly problematic when preparing pharmaceutical formulations, because aggregated proteins have been known to be immunogenic (Cleland et al. (1993), *Crit. Rev. Therapeutic Drug Carrier Systems*, 10:307-377; Robbins et al. (1987), *Diabetes*, 36:838-845; and Pinckard et al. (1967), *Clin. Exp. Immunol.*, 2:331-340).

Native KGF comprises five cysteine residues, namely amino acids 1, 15, 40, 102, and 106 (Finch et al. (1989), *Science*, 24:752-755). Although the cysteine content of native KGF was reported, what has not been reported are the roles played by cysteine residues with respect to activity (e.g., essentiality to biological activity) and tertiary structure (e.g., proclivity to form undesirable intermolecular or intramolecular disulfide bonds). Thus, there is no prior art teaching of which, if any, cysteine residues are essential or are involved in undesirable disulfide bond formation, making the protein susceptible to aggregation and/or instability.

In order to attempt to improve or otherwise alter one or more of the characteristics of native KGF, protein engineering may be employed. Recombinant DNA technology has been utilized to modify the sequences of native KGF.

Ron et al. (1993), *J. Biol. Chem.*, 268(4):2984-2988 reported modified KGF polypeptides

- 4 -

having 3, 8, 27, 38 or 49 amino acids deleted from the N-terminus. Those polypeptides missing 3, 8, or 27 N-terminal residues retained heparin binding ability; the others did not. Also, the polypeptides missing 3 and 8 residues were reported as being fully active, whereas the form missing 27 residues was 10-20 fold less mitogenic, and the forms lacking 38 or 49 amino acids did not have mitogenic activity. The stability of the modified KGF polypeptides was not discussed or otherwise reported.

Published PCT application no. 90/08771, *supra*, also reported the production of a chimeric protein wherein about the first 40 N-terminal amino acids of the mature form of native KGF were combined with the C-terminal portion (about 140 amino acids) of aFGF. The chimera was reported to target keratinocytes like KGF, but it lacked susceptibility to heparin, a characteristic of aFGF but not KGF. The stability of the chimera was not discussed or otherwise reported.

Thus, the literature has not reported a modified KGF molecule having significantly improved stability relative to native KGF. Moreover, the literature has not reported sufficient teachings or evidence to provide a reasonable expectation of successfully generating KGF molecules with such desirable characteristics.

Generally, the effects upon biological activity of any amino acid change upon a protein will vary depending upon a number of factors, including the three-dimensional structure of the protein and whether or not the modifications are to the receptor binding region of the primary sequence of the protein. As neither the three-dimensional structure nor the receptor binding region on the primary structure of native KGF has been published, the knowledge within the art does not permit generalization about the effects of amino

- 5 -

acid modifications to native KGF based upon the effects of amino acid modifications on even commonly categorized proteins.

It is the object of this invention to provide polypeptide molecules encoding such analogs that exhibit enhanced stability (e.g., when subjected to typical pH, thermal and/or other storage conditions) as compared to native KGF.

Summary of the Invention

The present invention provides novel, biologically active polypeptide analogs of KGF. For purposes of this invention, the term "KGF" includes native KGF and proteins characterized by a peptide sequence substantially the same as the peptide sequence of native KGF which retains cysteine residues corresponding to Cys¹ and Cys¹⁵ of native KGF (Cys³² and Cys⁴⁶ of SEQ ID NO:2) and which retains some or all of the biological activity of native KGF, particularly non-fibroblast epithelial cell proliferation. By "characterized by a peptide sequence substantially the same as the peptide sequence of native KGF" is meant a peptide sequence which is encoded by a DNA sequence capable of hybridizing to nucleotides 201 to 684 of SEQ ID NO:1, preferably under stringent hybridization conditions.

The determination of a corresponding amino acid position between two amino acid sequences may be determined by aligning the two sequences to maximize matches of residues including shifting the amino and/or carboxyl terminus, introducing gaps as required and/or deleting residues present as inserts in the candidate. Database searches, sequence analysis and manipulations may be performed using one of the well-known and routinely used sequence homology/identity scanning

- 6 -

algorithm programs (e.g., Pearson and Lipman (1988),
Proc. Natl. Acad. Sci. U.S.A., 85:2444-2448; Altschul et
al. (1990), *J. Mol. Biol.*, 215:403-410; Lipman and
Pearson (1985), *Science*, 222:1435 or Devereux et al.
5 (1984), *Nuc. Acids Res.*, 12:387-395).

Stringent conditions, in the hybridization
context, will be stringent combined conditions of salt,
temperature, organic solvents and other parameters
typically controlled in hybridization reactions.
10 Exemplary stringent hybridization conditions are
hybridization in 4 X SSC at 62-67° C., followed by
washing in 0.1 X SSC at 62-67° C. for approximately an
hour. Alternatively, exemplary stringent hybridization
conditions are hybridization in 45-55% formamide, 4 X
15 SSC at 40-45°C. [See, T. Maniatis et. al., *Molecular
Cloning (A Laboratory Manual)*; Cold Spring Harbor
Laboratory (1982), pages 387 to 389].

Thus, the proteins include allelic variations,
or deletion(s), substitution(s) or insertion(s) of amino
20 acids, including fragments, chimeric or hybrid molecules
of native KGF. One example of KGF includes charge-
change polypeptides wherein one or more of amino acid
residues 41-154 of native KGF (preferably residues Arg⁴¹,
Gln⁴³, Lys⁵⁵, Lys⁹⁵, Lys¹²⁸, Asn¹³⁷, Gln¹³⁸, Lys¹³⁹,
25 Arg¹⁴⁴, Lys¹⁴⁷, Gln¹⁵², Lys¹⁵³ or Thr¹⁵⁴) are deleted or
substituted with a neutral residue or negatively charged
residue selected to effect a protein with a reduced
positive charge (as taught in commonly owned U.S.S.N.
08/323,337, filed on October 13, 1994), specifically
30 including R(144)Q, a KGF having a substitution of
glutamine for arginine at amino acid positions 144 of
native KGF. Another example of KGF includes proteins
generated by substituting at least one amino acid having
a higher loop-forming potential for at least one amino
35 acid within a loop-forming region of Asn¹¹⁵-His¹¹⁶-
Tyr¹¹⁷-Asn¹¹⁸-Thr¹¹⁹ of native KGF (as taught in

- 7 -

commonly owned U.S.S.N. 08/323,473, filed on October 13, 1994), specifically including H(116)G, a KGF having a substitution of glycine for histidine at amino acid position 116 of native KGF. A still further example
5 includes proteins having one or more amino acid substitutions, deletions or additions within a region of 123-133 (amino acids 154-164 of SEQ ID NO:2) of native KGF; these proteins may have agonistic or antagonistic activity.

10 Surprisingly, it has been discovered when a KGF molecule (i.e., parent molecule) having cysteine residues corresponding (as determined using techniques described above) to Cys¹ and Cys¹⁵ of native KGF
15 (cysteine residues 32 and 46 of SEQ ID NO:2) is modified by replacing the corresponding cysteines, the resultant KGF analog has improved stability as compared to the parent molecule. Preferably, in addition to having increased stability, the invention is directed to those
20 analogs which also exhibit full biological activity (i.e., at least substantially similar receptor binding or affinity) as compared to native KGF.

In another aspect of the invention, purified and isolated nucleic acid molecules encoding the various biologically active polypeptide analogs of KGF are
25 described. In one embodiment, such nucleic acids comprise DNA molecules cloned into biologically functional plasmid or viral vectors. In another embodiment, nucleic acid constructs may then be utilized to stably transform a procaryotic or eucaryotic host
30 cell. In still another embodiment, the invention involves a process wherein either a procaryotic (preferably *E. coli*) or eucaryotic host cell stably transformed with a nucleic acid molecule is grown under suitable nutrient conditions in a manner allowing the
35 expression of the KGF analog. Following expression, the

- 8 -

resultant recombinant polypeptide can be isolated and purified.

A further aspect of the invention concerns pharmaceutical formulations comprising a therapeutically effective amount of a KGF analog and an acceptable pharmaceutical carrier. Such formulations will be useful in treating patients afflicted with epithelial diseases and injuries.

In this vein, another aspect relates to methods of stimulating epithelial cell growth by administering to a patient a therapeutically effective amount of a KGF analog. In one embodiment, non-fibroblast epithelial cells are the cells whose proliferation is stimulated. Such epithelial cells include various adnexal cells, pancreatic cells, liver cells, and mucosal epithelium in the respiratory and gastrointestinal tracts.

- 9 -

Brief Description of the Figures

Figure 1 shows the nucleotide (SEQ ID NO:1) and amino acid (SEQ ID NO:2) sequences of native KGF (the nucleotides encoding the mature form of native KGF is depicted by bases 201 to 684 of SEQ ID NO:1 and the mature form of KGF is depicted by amino acid residues 32 to 194 of SEQ ID NO:2).

Figures 2A, 2B and 2C show the plasmid maps of pCFM1156, pCFM1656 and pCFM3102, respectively.

Figure 3 shows the nucleotide (SEQ ID NO:3) and amino acid (SEQ ID NO:4) sequences of the construct RSH-KGF.

Figure 4 shows the nucleotide (SEQ ID NO:5) and amino acid (SEQ ID NO:6) sequences of the construct contained in plasmid KGF.

Figure 5 shows the chemically synthesized OLIGOs (OLIGO#6 through OLIGO#11; SEQ ID NO:12-17, respectively) used to substitute the DNA sequence between a KpnI site and an EcoRI site (from amino acid positions 46 to 85 of SEQ ID No:6) in the construct contained in plasmid KGF to produce the construct in plasmid KGF(dsd).

Figure 6 shows the chemically synthesized OLIGOs (OLIGO#12 through OLIGO#24; SEQ ID NO:18-30, respectively) used to construct KGF (codon optimized).

Figure 7 shows the nucleotide (SEQ ID NO:31) and amino acid (SEQ ID NO:32) sequences of C(1,15)S, a KGF analog having substitutions of serine for cysteine at amino acid positions 1 and 15 of native KGF.

Figure 8 shows the nucleotide (SEQ ID NO:33) and amino acid (SEQ ID NO:34) sequences of Δ N3/C(15)S, a KGF analog having a deletion of the first 3 amino acids of the N-terminus and a substitution of serine for cysteine at amino acid position 15 of native KGF.

- 10 -

Figure 9 shows the nucleotide (SEQ ID NO:35) and amino acid (SEQ ID NO:36) sequences of $\Delta N3/C(15)-$, a KGF analog having a deletion of the first 3 amino acids of the N-terminus and a deletion of cysteine at amino acid position 15 of native KGF.

Figure 10 shows the nucleotide (SEQ ID NO:37) and amino acid (SEQ ID NO:38) sequences of $\Delta N8/C(15)S$, a KGF analog having a deletion of the first 8 amino acids of the N-terminus and a substitution of serine for cysteine at amino acid position 15 of native KGF.

Figure 11 shows the nucleotide (SEQ ID NO:39) and amino acid (SEQ ID NO:40) sequences of $\Delta N8/C(15)-$, a KGF analog having a deletion of the first 8 amino acids of the N-terminus and a deletion of cysteine at amino acid position 15 of native KGF.

Figure 12 shows the nucleotide (SEQ ID NO:41) and amino acid (SEQ ID NO:42) sequences of $\Delta N15$, a KGF analog having a deletion of the first 15 amino acids of the N-terminus of native KGF.

Figure 13 shows the nucleotide (SEQ ID NO:43) and amino acid (SEQ ID NO:44) sequences of $\Delta N16$, a KGF analog having a deletion of the first 16 amino acids of the N-terminus of native KGF.

Figure 14 shows the nucleotide (SEQ ID NO:45) and amino acid (SEQ ID NO:46) sequences of $\Delta N17$, a KGF analog having a deletion of the first 17 amino acids of the N-terminus of native KGF.

Figure 15 shows the nucleotide (SEQ ID NO:47) and amino acid (SEQ ID NO:48) sequences of $\Delta N18$, a KGF analog having a deletion of the first 18 amino acids of the N-terminus of native KGF.

Figure 16 shows the nucleotide (SEQ ID NO:49) and amino acid (SEQ ID NO:50) sequences of $\Delta N19$, a KGF analog having a deletion of the first 19 amino acids of the N-terminus of native KGF.

- 11 -

Figure 17 shows the nucleotide (SEQ ID NO:51) and amino acid (SEQ ID NO:52) sequences of Δ N20, a KGF analog having a deletion of the first 20 amino acids of the N-terminus of native KGF.

5 Figure 18 shows the nucleotide (SEQ ID NO:53) and amino acid (SEQ ID NO:54) sequences of Δ N21, a KGF analog having a deletion of the first 21 amino acids of the N-terminus of native KGF.

10 Figure 19 shows the nucleotide (SEQ ID NO:55) and amino acid (SEQ ID NO:56) sequences of Δ N22, a KGF analog having a deletion of the first 22 amino acids of the N-terminus of native KGF.

15 Figure 20 shows the nucleotide (SEQ ID NO:57) and amino acid (SEQ ID NO:58) sequences of Δ N23, a KGF analog having a deletion of the first 23 amino acids of the N-terminus of native KGF.

20 Figure 21 shows the nucleotide (SEQ ID NO:59) and amino acid (SEQ ID NO:60) sequences of Δ N24, a KGF analog having a deletion of the first 24 amino acids of the N-terminus of native KGF.

25 Figure 22 shows the nucleotide (SEQ ID NO:61) and amino acid sequences (SEQ ID NO:62) of C(1,15)S/R(144)E, a KGF analog having substitutions of serine for cysteine at amino acid positions 1 and 15 and a substitution of glutamic acid for arginine at amino acid position 144 of native KGF.

30 Figure 23 shows the nucleotide (SEQ ID NO:63) and amino acid (SEQ ID NO:64) sequences of C(1,15)S/R(144)Q, a KGF analog having substitutions of serine for cysteine at amino acid positions 1 and 15 and a substitution of glutamine for arginine at amino acid position 144 of native KGF.

35 Figure 24 shows the nucleotide (SEQ ID NO:65) and amino acid (SEQ ID NO:66) sequences of Δ N23/R(144)Q, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamine

- 12 -

for arginine at amino acid position 144 of native KGF.

Figure 25 shows the amount of remaining soluble protein when native KGF and C(1,15)S were stored in 20 mM Na phosphate, 0.15 M NaCl, pH 7.0 at 37°C for 5 27 hrs.

Figure 26 shows the amount of remaining soluble protein when native KGF and C(1,15)S were stored in 0.15 M NaCl, 20 mM NaPO₄, 0.15 M NaCl, pH 7.0 at 37°C for 27 hrs.

10 Figure 27 shows the amount of remaining soluble protein when native KGF, ΔN15 and C(1,15)S were stored in 50 mM NaPO₄, 0.15 M NaCl, pH 7.0 at 37°C for 27 hrs.

Figure 28 shows the amount of soluble protein, 15 determined by size exclusion HPLC, as a function of incubation time at 37°C.

Figure 29 shows the estimated melting temperature (T_m) as a function of pH for native KGF, C(1,15)S/R(144)Q and C(1,15)S/R(144)E.

20 Figure 30 shows a typical profile of mitogenic activity of C(1,15)S determined by measuring the incorporation of [³H]-Thymidine during DNA synthesis by comparing it to a native KGF standard curve.

Figure 31 shows a typical profile of the 25 mitogenic activity of ΔN15 determined by measuring the incorporation of [³H]-Thymidine during DNA synthesis and by comparing it to a native KGF standard curve.

Figure 32 shows a typical profile of the mitogenic activity of ΔN23 determined by measuring the 30 incorporation of [³H]-Thymidine during DNA synthesis and by comparing it to a native KGF standard curve.

Figure 33 shows a typical profile of the mitogenic activity of ΔN23/R(144)Q determined by measuring the incorporation of [³H]-Thymidine during DNA 35 synthesis and by comparing it to a native KGF standard curve.

- 13 -

Figure 34 shows a typical profile of the mitogenic activity of C(1,15)S/R(144)Q determined by measuring the incorporation of [³H]-Thymidine during DNA synthesis and by comparing it to a native KGF standard curve.

Figure 35 shows a typical profile of the mitogenic activity of C(1,15)S/R(144)E determined by measuring the incorporation of [³H]-Thymidine during DNA synthesis and by comparing it to a native KGF standard curve.

Figure 36 shows the effects of C(1,15)S and ΔN23 on serum chemistries.

Figure 37 shows the nucleotide (SEQ ID NO:77) and amino acid (SEQ ID NO:78) sequences of C(1,15,40)S, a KGF analog having substitutions of serine for cysteine at amino acid positions 1, 15 and 40 of native KGF.

Figure 38 shows the nucleotide (SEQ ID NO:79) and amino acid (SEQ ID NO:80) sequences of C(1,15,102)S, a KGF analog having substitutions of serine for cysteine at amino acid positions 1, 15 and 102 of native KGF.

Figure 39 shows the nucleotide (SEQ ID NO:81) and amino acid (SEQ ID NO:82) sequences of C(1,15,102,106)S, a KGF analog having substitutions of serine for cysteine at amino acid positions 1, 15, 102 and 106 of native KGF.

Figure 40 shows the nucleotide (SEQ ID NO:83) and amino acid (SEQ ID NO:84) sequences of ΔN23/N(137)E, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamic acid for asparagine at amino acid position 137 of native KGF.

Figure 41 shows the nucleotide (SEQ ID NO:85) and amino acid (SEQ ID NO:86) sequences of ΔN23/K(139)E, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamic

- 14 -

acid for lysine at amino acid position 139 of native KGF.

Figure 42 shows the nucleotide (SEQ ID NO:87) and amino acid (SEQ ID NO:88) sequences of Δ N23/K(139)Q, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamine for lysine at amino acid position 139 of native KGF.

Figure 43 shows the nucleotide (SEQ ID NO:89) and amino acid (SEQ ID NO:90) sequences of Δ N23/R(144)A, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of alanine for arginine at amino acid position 144 of native KGF.

Figure 44 shows the nucleotide (SEQ ID NO:91) and amino acid (SEQ ID NO:92) sequences of Δ N23/R(144)E, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamic acid for arginine at amino acid position 144 of native KGF.

Figure 45 shows the nucleotide (SEQ ID NO:93) and amino acid (SEQ ID NO:94) sequences of Δ N23/R(144)L, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of leucine for arginine at amino acid position 144 of native KGF.

Figure 46 shows the nucleotide (SEQ ID NO:95) and amino acid (SEQ ID NO:96) sequences of Δ N23/K(147)E, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamic acid for lysine at amino acid position 147 of native KGF.

Figure 47 shows the nucleotide (SEQ ID NO:97) and amino acid (SEQ ID NO:98) sequences of Δ N23/K(147)Q, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamine for lysine at amino acid position 147 of native KGF.

Figure 48 shows the nucleotide (SEQ ID NO:99) and amino acid (SEQ ID NO:100) sequences of

- 15 -

ΔN23/K(153)E, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamic acid for lysine at amino acid position 153 of native KGF.

5 Figure 49 shows the nucleotide (SEQ ID NO:101) and amino acid (SEQ ID NO:102) sequences of ΔN23/K(153)Q, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a substitution of glutamine for lysine at amino acid
10 position 153 of native KGF.

 Figure 50 shows the nucleotide (SEQ ID NO:103) and amino acid (SEQ ID NO:104) sequences of ΔN23/Q(152)E/K(153)E, a KGF analog having a deletion of the first 23 amino acids of the N-terminus and a
15 substitution of glutamic acid for glutamine at amino acid position 152 of native KGF and glutamic acid for lysine at amino acid position 153 of native KGF.

 Figure 51 shows the effect of ΔN23 on streptozotocin-induced diabetes in Sprague-Dawley rats.
20

Detailed Description

 In accordance with the present invention, novel analogs of KGF are provided. It has now been
25 determined that four of the cysteine residues of native KGF (Cys¹ and Cys¹⁵, and Cys¹⁰² and Cys¹⁰⁶) are involved in the formation of two disulfide bridges. Cys⁴⁰ is not involved in intramolecular disulfide formation. Hence, KGF contains two small disulfide loops separated by
30 almost 90 amino acids. Based upon first principals, the determination of which cysteine residues are involved in the disulfide bridges suggests which cysteines are free to form undesirable intermolecular crosslinks or
 intramolecular bonds that cause the protein to adopt an
35 undesirable tertiary structure (e.g., a conformation that reduces the activity of the protein).

- 16 -

Surprisingly, it has been found that modifying a KGF by deleting or substituting amino acid residues for the cysteine residues corresponding to positions 1 and 15 of KGF (positions 32 and 46 of SEQ ID NO:2) produces a KGF analog having substantially improved stability (i.e., reduced problems caused by improper refolding, intermolecular disulfide formation and/or protein aggregation). For example, the KGF analogs will generally be purified in a greater yield of soluble, correctly folded protein. Moreover, once the material is purified, it will be more stable to pH, temperature, etc. as compared to the stability of the parent molecule. Although not intended to be bound by theory, it is believed that Cys¹ and Cys¹⁵ of KGF in addition to forming an intramolecular disulfide bridge and an N-terminal disulfide loop, under certain conditions also exist as free cysteines which are capable of forming intermolecular disulfide bridges, resulting in protein instability and aggregation. Moreover, it has been discovered that deletion of the N-terminal disulfide loop is not important for receptor binding or mitogenic activity.

As used in this invention, a "KGF analog" or a "polypeptide analog of KGF" shall mean any of the described naturally and non-naturally occurring polypeptides differing in structure from a KGF by possessing modifications in peptide sequence corresponding to the 24 amino acid N-terminus of the KGF (amino acids 32 to 55 of SEQ ID NO:2), wherein Cys¹ and Cys¹⁵ of the KGF (amino acids 32 to 46 of SEQ ID NO:2) are replaced or deleted. The manner by which the cysteines are replaced or deleted is not significant and includes, for example, polypeptide analogs incorporating one or more amino acid deletions and/or substitutions. Accordingly, the invention provides a family of novel

- 17 -

keratinocyte growth factor proteins. This family comprises several groups of proteins.

One group of KGF analogs includes molecules in which the cysteines at positions 1 and 15 of a KGF are replaced with amino acids, including those that do not occur naturally in proteins. Strategies for generating the substitution analogs include using site-directed mutagenesis (Ho et al. (1989), *Gene*, 77:51-59; Innis et al. "PRC Protocols", Academic Press, Inc., San Diego, CA). [KGF analogs comprising an amino acid substitution are referred to by the residue found at that position in the mature protein (minus signal sequence) set forth in SEQ ID NO:2, followed by that amino acid position in parentheses and the new amino acid. For instance, an analog comprising a cysteine to serine substitution at amino acid position 15 of KGF (position 46 of SEQ ID NO:2) is referred to as "C(15)S".] Preferably, the cysteine is converted to a neutral amino acid such as glycine, valine, alanine, leucine, isoleucine, tyrosine, phenylalanine, histidine, tryptophan, serine, threonine and methionine, with serine, threonine and alanine being most preferred because of their chemical similarity to cysteine. Example 1 details the generation of C(1,15)S using partial gene synthesis (in conjunction with other recombinant techniques) followed by recombinant expression in a stably transformed bacterial host.

Another group of KGF analogs includes molecules that have the cysteines at positions 1 and 15 deleted from KGF. Different strategies may be employed in developing such KGF analogs, such as N-terminal truncations and site-specific deletions, or a combination of both.

An "N-terminal truncation" refers to a modification of a KGF wherein 1 to 24 N-terminal amino acid residues of the KGF (amino acids 32 to 55 of SEQ ID NO:2), including Cys¹ and Cys¹⁵, have been deleted.

- 18 -

[KGF analogs comprising a truncation of amino acids will be referred to by the residue deleted at that position in the mature protein (minus signal sequence) set forth in SEQ ID NO:2, beginning with the site of the deletion and by the number of residues deleted. For instance, a KGF analog comprising an N-terminal truncation of 24 residues of the KGF (residues 1-55 of SEQ ID NO:2) will be referred to as a "ΔN24" analog.] Specifically included within this group are ΔN23 analogs of native KGF wherein one or more of amino acid residues 41-154 (amino acids 72-185 of SEQ ID NO:2), specifically including amino acid residues 123-133 (amino acids 154-164 of SEQ ID NO:2), are deleted or substituted with a neutral residue or negatively charged residue selected to effect a protein with a reduced positive charge. Preferred residues for modification are Arg⁴¹, Gln⁴³, Lys⁵⁵, Lys⁹⁵, Lys¹²⁸, Asn¹³⁷, Gln¹³⁸, Lys¹³⁹, Arg¹⁴⁴, Lys¹⁴⁷, Gln¹⁵², Lys¹⁵³ or Thr¹⁵⁴, with Gln¹³⁸, Lys¹³⁹, Arg¹⁴⁴, Lys¹⁴⁷, Gln¹⁵² or Lys¹⁵³ being more preferred and Arg¹⁴⁴ being most preferred. Also included within this group are ΔN23 analogs of native KGF having loop-forming modifications within a loop-forming region of Asn¹¹⁵-His¹¹⁶-Tyr¹¹⁷-Asn¹¹⁸-Thr¹¹⁹ (amino acids 146-150 of SEQ ID NO:2), preferably including a charge-change modification of amino acid residue 116, more preferably the substitution of Gly at position 116. Further still, included in this group are ΔN23 analogs of native KGF having one or more amino acid substitutions, deletions or additions within a region of 123-133 (amino acids of 154-164 SEQ ID NO:2) of native KGF.

Example 1 details the generation of systematic N-terminal truncations accomplished using partial gene synthesis, in conjunction with other recombinant techniques, followed by recombinant expression in a stably transformed bacterial host. Such exemplified N-terminal truncations include ΔN15 to ΔN24. Moreover,

- 19 -

Example 3 details expression in mammalian cell culture cells of DNA encoding native KGF and heterogeneous N-terminal glycosylated isoforms, the purification of preferably a glycosylated isoform having an N-terminal truncation of amino acids 1-23 of the mature form of native KGF.

In contrast, a site-specific deletion refers to a modification of a KGF wherein one or more amino acid residues (e.g., Cys¹ or Cys¹⁵) are removed. When a Cys¹ or Cys¹⁵ of the KGF is specifically deleted, the analog is one amino acid shorter than the KGF. [KGF analogs comprising an amino acid deletion are referred to by the residue found at that position in the mature protein (minus signal sequence) set forth in SEQ ID NO:2, followed by that amino acid position in parentheses, and a negative sign. For instance, an analog within this group comprising a deletion of cysteine at position 15 of the KGF (position 36 of SEQ ID NO:2) is referred to as "C(15)-".] The site-specific deletions may be generated using site directed mutagenesis, as described above.

Also included within this group are analogs in which Cys¹ and Cys¹⁵ of a KGF are removed through truncation and deletion. For example, representative KGF analogs comprise the truncation of the first three amino terminal residues (Cys-Asn-Asp) of the KGF or the truncation of the first eight amino acids (Cys-Asn-Asp-Met-Thr-Pro-Glu-Gln) of the KGF coupled with the deletion of cysteine at amino acid position 15 of KGF (these analogs are referred to as Δ N3/C(15)- and Δ N8/C(15)-, respectively). As a methionine residue occurs naturally at the fourth and ninth amino acid position in native KGF, no additional Met codon is required to enable proper initiation of translation.

A still further group includes molecules in which the cysteines at positions 1 and 15 of KGF are

- 20 -

replaced through truncation and substitution. For example, representative KGF analogs are $\Delta N3/C(15)S$, and $\Delta N8/C(15)S$. Such analogs comprise the truncation of the first three amino-terminal residues of a KGF or the
5 deletion of the first eight amino-terminal residues of a KGF coupled with the substitution of cysteine at amino acid position 15 with another amino acid, for instance, serine.

When the KGF analogs are biologically
10 generated, i.e., are the products of cellular expression as opposed to the products of solid state synthesis, proteolytic or enzymatic derivatization of naturally-occurring products, etc., the nucleic acids encoding such polypeptides, will differ in one or more
15 nucleotides as compared to the native KGF nucleotide sequence. Such nucleotides may be expressed and the resultant polypeptide purified by any one of a number of recombinant technology methods known to those skilled in the art.

20 DNA sequences coding for all or part of the KGF analogs may include among other things the incorporation of codons "preferred" for expression in selected host cells (e.g., "*E. coli* expression codons"); the provision of sites for cleavage by restriction
25 enzymes; and the provision of additional initial, terminal, or intermediate nucleotide sequences (e.g., an initial methionine amino acid residue for expression in *E. coli* cells), to facilitate construction of readily expressed vectors.

30 The present invention also provides recombinant molecules or vectors for use in the method of expression of the polypeptides. Such vectors may be comprised of DNA or RNA and can be circular, linear, single-stranded or double-stranded in nature and can be
35 naturally-occurring or assemblages of a variety of components, be they naturally-occurring or synthetic.

- 21 -

Many examples of such expression vectors are known. The components of the vectors, e.g. replicons, selection genes, enhancers, promoters, and the like, may be obtained from natural sources or synthesized by known procedures. In each case, expression vectors useful in this invention will contain at least one expression control element functionally associated with the inserted nucleic acid molecule encoding the KGF polypeptide analog. This control element is responsible for regulating polypeptide expression from the nucleic acid molecules of the invention. Useful control elements include, for example, the *lac* system, the *trp* system, the operators and promoters from phage λ , a glycolytic yeast promoter, a promoter from the yeast acid phosphatase gene, a yeast alpha-mating factor, and promoters derived from adenovirus, Epstein-Barr virus, polyoma, and simian virus as well as those from various retroviruses. However, numerous other vectors and control elements suitable for procaryotic or eucaryotic expression are known in the art and may be employed in the practice of this invention.

Examples of suitable procaryotic cloning vectors may include plasmids from *E. coli* (e.g. pBR322, col E1, pUC, and the F-factor), with preferred plasmids being pCFM1156 (ATCC 69702), pCFM1656 (ATCC 69576) and pCFM3102 (described in the Examples section, below). Other appropriate expression vectors of which numerous types are known in the art for mammalian, insect, yeast, fungal and bacterial expression can also be used for this purpose. The transfection of these vectors into appropriate host cells can result in expression of the KGF analog polypeptides.

Host microorganisms useful in this invention may be either procaryotic or eucaryotic. Suitable procaryotic hosts include various *E. coli* (e.g., FM5, HB101, DH5 α , DH10, and MC1061), *Pseudomonas*, *Bacillus*,

- 22 -

and *Streptomyces* strains, with *E. coli* being preferred. Suitable eucaryotic host cells include yeast and other fungi, insect cells, plant cells and animal cells, such as COS (e.g., COS-1 and COS-7) and CV-1 monkey cell
5 lines, 3T3 lines derived from Swiss, Balb-c or NIH cells, HeLa and L-929 mouse cells, and CHO, BHK or HaK hamster cells. Depending upon the host employed, recombinant polypeptides produced in accordance herewith will be glycosylated with mammalian or other eucaryotic
10 carbohydrates or may be non-glycosylated.

The preferred production method will vary depending upon many factors and considerations; the optimum production procedure for a given situation will be apparent to those skilled in the art through minimal
15 experimentation. The resulting expression product may then be purified to near homogeneity using procedures known in the art. A typical purification procedure for procaryotic cell production involves rupturing the cell walls by high pressure or other means, centrifugation or
20 filtration to remove cellular debris followed by ion exchange chromatography of supernatant or filtrate and, finally, hydrophobic interaction chromatography. If the analog is expressed in insoluble form, another purification technique involves first solubilizing the
25 inclusion bodies containing the analogs followed by ion exchange chromatography, then refolding of the protein, and, finally, hydrophobic interaction chromatography. Exemplary purification techniques are taught in commonly owned U.S.S.N. 08/323,339, filed on October 13, 1994.
30 Generally, U.S.S.N. 08/323,339 teaches a method for purifying a keratinocyte growth factor comprising: (a) obtaining a solution comprising the KGF; (b) binding the KGF from the solution of part (a) to a cation exchange resin; (c) eluting the KGF in an eluate solution from
35 the cation exchange resin; (d) either passing the eluate solution from part (c) through an appropriate molecular

- 23 -

weight exclusion matrix or performing hydrophobic interaction chromatography on the eluate solution of part (c); and (e) recovering the KGF from the molecular weight exclusion matrix or hydrophobic interaction chromatography.

Of course, the analogs may be rapidly screened to assess their physical properties. The Examples section set forth various well-known stability assays, although the specific assay used to test the analog is not critical. Moreover, the level of biological activity (e.g., receptor binding and/or affinity, mitogenic, cell proliferative and/or *in vivo* activity) may also be tested using a variety of assays, some of which are set forth in the Examples section. Numerous assays are well-known and can be used to quickly screen the KGF analogs to determine whether or not they possess acceptable biological activity. One such assay specifically tests the KGF analogs for the ability to bind to the KGF receptor (KGFR) by competing with ¹²⁵I-KGF binding (Bottaro et al. (1990), *J. Biol. Chem.*, 265:12767-12770; Ron et al. (1993), *J. Biol. Chem.*, 268:2984-2988). An alternative method for assaying KGFR/KGF analog interactions involves the use of techniques such as real time biospecific interaction analysis (BIA) (Felder et al. (1993), *Molecular & Cellular Biology*, 13:1449-1455). Additionally a mitogenic assay can be utilized to test the ability of the KGF analogs to stimulate DNA synthesis (Rubin et al. (1989), *supra*). Finally, cell proliferative assays can be utilized to test the ability of the KGF analogs to stimulate cell proliferation (Falco, et al. (1988), *Oncogene*, 2:573-578). Using any of the aforementioned assay systems, KGF analogs can be rapidly screened for their biological activity.

In a preferred embodiment, the present invention is directed to KGF analogs which retain the

- 24 -

full (i.e., at least substantially similar) *in vitro* or *in vivo* biological activity to that of native KGF. Exemplary KGF analogs with these properties, as determined by one or more of the above assays,
5 are C(1,15)S, Δ N3/C(15)S, Δ N3/C(15)-, Δ N8/C(15)S, Δ N8/C(15)-, Δ N15, Δ N16, Δ N17, Δ N18, Δ N19, Δ N20, Δ N21, Δ N22, Δ N23, Δ N24 or Δ N23/R(144)Q.

The KGF analogs may be further modified to contain additional chemical moieties not normally a part
10 of the peptide. Such derivatized moieties may improve the solubility, absorption, biological half life, and the like of the KGF analog. The moieties may alternatively eliminate or attenuate any undesirable side effects of the protein and the like. Moieties
15 capable of mediating such effects are disclosed, for example, in *REMINGTON'S PHARMACEUTICAL SCIENCES*, 18th ed., Mack Publishing Co., Easton, PA (1990). Covalent modifications may be introduced into the molecule by reacting targeted amino acid residues of the peptide
20 with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues (T.E. Creighton (1983), *PROTEINS: STRUCTURE AND MOLECULE PROPERTIES*, W.H. Freeman & Co., San Francisco, pp. 79-86). Polyethylene glycol ("PEG") is one such
25 chemical moiety which has been used in the preparation of therapeutic protein products. For some proteins, the attachment of polyethylene glycol has been shown to protect against proteolysis, Sada, et al.(1991), *J. Fermentation Bioengineering*, 71:137-139, and methods
30 for attachment of certain polyethylene glycol moieties are available. See U.S. Patent No. 4,179,337, Davis et al., "Non-Immunogenic Polypeptides," issued December 18, 1979; and U.S. Patent No. 4,002,531, Royer, "Modifying enzymes with Polyethylene Glycol and Product Produced
35 Thereby," issued January 11, 1977. For a review, see Abuchowski et al., in *Enzymes as Drugs*. (Holcerberg and

- 25 -

Roberts, (eds.) pp. 367-383 (1981)). For polyethylene glycol, a variety of means have been used to attach the polyethylene glycol molecules to the protein. Generally, polyethylene glycol molecules are connected to the protein via a reactive group found on the protein. Amino groups, such as those on lysine residues or at the N-terminus, are convenient for such attachment. For example, Royer (U.S. Pat. No. 4,002,531, above) states that reductive alkylation was used for attachment of polyethylene glycol molecules to an enzyme. EP 0 539 167, published April 28, 1993, Wright, "Peg Imidates and Protein Derivates Thereof" states that peptides and organic compounds with free amino group(s) are modified with an imidate derivative of PEG or related water-soluble organic polymers. U.S. Patent No. 4,904,584, Shaw, issued February 27, 1990, relates to the modification of the number of lysine residues in proteins for the attachment of polyethylene glycol molecules via reactive amine groups.

In yet another embodiment, the present invention is directed to a single-dose administration unit of a medicinal formulation, which can be safely administered parenterally or orally to treat a disease in a warm-blooded animal (such as a human). Such medicinal formulation may be in the form of a lyophilized or otherwise dehydrated therapeutic or diagnostic which can be reconstituted by the addition of a physiologically acceptable solvent. The solvent may be any media such as sterile water, physiological saline solution, glucose solution or other aqueous carbohydrates (e.g., polyols such as mannitol, xylitol or glycerol) which is capable of dissolving the dried composition, which is compatible with the selected administration route and which does not negatively interfere with the active principle and the reconstitution stabilizers employed. In a specific

- 26 -

embodiment, the present invention is directed to a kit for producing the single-dose administration unit. The kit contains both a first container having a dried protein and a second container having an aqueous formulation comprising a reconstitution stabilizer. As for the concentration of the protein in the solution, the solution volume which is charged into each container, and the capacity of the containers (interrelated parameters which can be suitably modified, depending upon the desired concentration of active principle in the end-dosage unit), these may vary within wide ranges well-known to skilled artisans.

KGF analogs according to the invention may be useful as therapeutic and diagnostic agents and as research reagents. Thus the KGF analogs may be used in *in vitro* and/or *in vivo* diagnostic assays to quantify the amount of KGF in a tissue or organ sample or to determine and/or isolate cells which express KGFR (Bottaro et al. (1990), *J. Biol. Chem.*, 265:12767-12770; Ron et al. (1993), *J. Biol. Chem.*, 268:2984-2988). In assays of tissues or organs there will be less radioactivity from ^{125}I -KGF analog binding to KGFR, as compared to a standardized binding curve of ^{125}I -KGF analog, due to unlabeled native KGF binding to KGFR. Similarly, the use of ^{125}I -KGF analog may be used to detect the presence of KGFR in various cell types.

This invention also contemplates the use of a KGF analog in the generation of antibodies made against the peptide, which antibodies also bind to native KGF. In this embodiment, the antibodies are monoclonal or polyclonal in origin and are generated using a KGF analog. The resulting antibodies bind preferentially to native KGF, preferably when that protein is in its native (biologically active) conformation. These antibodies can be used for detection or purification of the native KGF.

- 27 -

Moreover, the invention contemplates the use of the KGF analogs in the discovery of high affinity or low affinity KGF binding molecules having therapeutical applications, for example, as a way for efficient KGF
5 delivery or as an inhibitor for KGF activity. The thermal stability of the KGF analogs is important to identify such binding molecules in physiological conditions (i.e., at 37°C) since their affinity for KGF could be strongly temperature-dependent and may be
10 unpredictable from the affinity observed at 4°C.

For *in vivo* uses, the KGF analogs may be formulated with additives. Such additives include buffers, carriers, stabilizers, excipients, preservatives, tonicity adjusting agents, anti-oxidants
15 and the like (e.g., viscosity adjusting agents or extenders). The selection of specific additives will depend upon the storage form (i.e., liquid or lyophilized) and the modes of administering the KGF analog. Suitable formulations, known in the art, can be
20 found in *REMINGTON'S PHARMACEUTICAL SCIENCES* (latest edition), Mack Publishing Company, Easton, PA.

The KGF analogs may be applied in therapeutically effective amounts to tissues specifically characterized by having damage to or
25 clinically insufficient numbers of non-fibroblast epithelium cells. Areas in which KGF analogs may be successfully administered include, but are not limited to: the stimulation, proliferation and differentiation of adnexal structures such as hair follicles, sweat
30 glands, and sebaceous glands in patients with burns and other partial and full-thickness injuries; accelerated reepithelialization of lesions caused by epidermolysis bullosa, which is a defect in adherence of the epidermis to the underlying dermis, resulting in frequent open,
35 painful blisters which can cause severe morbidity; preventing chemotherapy-induced alopecia and treating

- 28 -

male-pattern baldness, or the progressive loss of hair in men and women; treating gastric and duodenal ulcers; treating inflammatory bowel diseases, such a Crohn's disease (affecting primarily the small intestine) and
5 ulcerative colitis (affecting primarily the large bowel); preventing or reducing gut toxicity in radiation and chemotherapy treatment regimes through treatment (e.g., pretreatment and/or posttreatment) to induce a cytoprotective effect or regeneration or both;
10 stimulating the production of mucus throughout the gastrointestinal tract; inducing the proliferation and differentiation of type II pneumocytes, which may help treat or prevent diseases such as hyaline membrane disease (i.e., infant respiratory distress syndrome and
15 bronchopulmonary dysplasia) in premature infants; stimulating the proliferation and differentiation of the bronchiolar and/or alveolar epithelium with acute or chronic lung damage or insufficiency due to inhalation injuries (including high oxygen levels), emphysema, use
20 of lung damaging chemotherapeutics, ventilator trauma or other lung damaging circumstances; increasing liver function to treat or prevent hepatic cirrhosis, fulminant liver failure, damage caused by acute viral hepatitis and/or toxic insults to the liver; inducing
25 corneal cell regeneration, for example in the treatment of corneal abrasion; inducing epithelial cell regeneration to treat progressive gum disease; inducing regeneration of tympanic epithelial cells to treat ear drum damage and treating or preventing the onset of
30 diabetes mellitus or as an adjunct in the setting of islet cell transplantation.

A patient in need of proliferation of non-fibroblast epithelial cells will be administered an effective amount of a KGF analog. An "effective amount"
35 is that amount of the KGF analog required to elicit the desired response in the patient being treated and will,

- 29 -

thus, generally be determined by the attending physician. Factors influencing the amount of KGF analog administered will include the age and general condition of the patient, the disease being treated, etc. Typical
5 dosages will range from 0.001 mg/kg body weight to 500 mg/kg body weight.

The KGF analog may be safely administered parenterally (e.g., via IV, IT, IM, SC, or IP routes), orally or topically to warm-blooded animals (such as
10 humans). The KGF analog may be used once or administered repeatedly, depending on the disease and the condition of the patient. In some cases, the KGF analog may be administered as an adjunct to other therapy and also with other pharmaceutical preparations.

15 The following examples are included to more fully illustrate the present invention. It is understood that modifications can be made in the procedures set forth, without departing from the spirit of the invention.

20

EXAMPLES

Standard methods for many of the procedures described in the following examples, or suitable
25 alternative procedures, are provided in widely recognized manuals of molecular biology such as, for example, *Molecular Cloning*, Second Edition, Sambrook et al., Cold Spring Harbor Laboratory Press (1987) and *Current Protocols in Molecular Biology*, Ausabel et al.,
30 Greene Publishing Associates/Wiley Interscience, New York (1990).

EXAMPLE 1: Preparation of DNA Coding for KGF and KGF Analogs

35 The cloning of the full-length human KGF gene (encoding a polypeptide with the sequence of native KGF)

- 30 -

was carried out both by polymerase chain reaction (PCR) of RNA from an animal cell and by PCR of chemically synthesized (*E. coli* optimized codon) oligonucleotides ("OLIGOs"). Both procedures are described below:

5 PCR amplification using RNA isolated from cells known to produce the polypeptide was performed. Initially, cells from a human fibroblast cell line AG1523A (obtained from Human Genetic Mutant Cell Culture Repository Institute For Medical Research, 10 Camden, New Jersey) were disrupted with guanidium thiocyanate, followed by extraction (according to the method of Chomyzinski et al. (1987), *Anal. Biochem.*, 172:156). Using a standard reverse transcriptase protocol for total RNA, the KGF cDNA was generated. 15 PCR (PCR#1) amplification of the KGF gene was carried out using the KGF cDNA as template and primers OLIGO#1 and OLIGO#2 that encode DNA sequences immediately 5' and 3' of the KGF gene [Model 9600 thermocycler (Perkin-Elmer Cetus, Norwalk, CT); 28 cycles; each 20 cycle consisting of one minute at 94°C for denaturation, two minutes at 60°C for annealing, and three minutes at 72°C for elongation]. A small aliquot of the PCR#1 product was then used as template for a second KGF PCR (PCR#2) amplification identical to the 25 cycle conditions described above except for a 50°C annealing temperature. For expression cloning of the KGF gene, nested PCR primers were used to create convenient restriction sites at both ends of the KGF gene. OLIGO#3 and OLIGO#4 were used to modify the KGF 30 DNA product from PCR#2 to include *MluI* and *BamHI* restriction sites at the 5' and 3' ends of the gene, respectively [PCR#3; 30 cycles; each cycle consisting of one minute at 94°C for denaturation, two minutes at 60°C for annealing, and three minutes at 72°C for 35 elongation]. This DNA was subsequently cut with *MluI* and *BamHI*, phenol extracted, and ethanol precipitated.

- 31 -

It was then resuspended and ligated (using T4 ligase) into a pCFM1156 plasmid (Figure 2A) that contained a "RSH" signal sequence to make construct RSH-KGF (Figure 3).

5 The ligation products were transformed (according to the method of Hanahan (1983), *J. Mol. Biol.*, 166:557) into *E. coli* strain FM5 (ATCC: 53911) and plated onto LB+kanamycin at 28°C. Several transformants were selected and grown in small liquid
10 cultures containing 20 µg/mL kanamycin. The RSH-KGF plasmid was isolated from the cells of each culture and DNA sequenced. Because of an internal *NdeI* site in the KGF gene, it was not possible to directly clone the native gene sequence into the desired expression vector
15 with the bracketed restriction sites of *NdeI* and *BamHI*. This was accomplished as a three-way ligation. Plasmid RSH-KGF was cut with the unique restriction sites of *BsmI* and *SstI*, and a ~3 kbp DNA fragment (containing the 3' end of the KGF gene) was isolated following
20 electrophoresis through a 1% agarose gel. A PCR (PCR#4) was carried out as described for PCR#3 except for the substitution of OLIGO#5 for OLIGO#3. The PCR DNA product was then cut with *NdeI* and *BsmI* and a 311 bp DNA fragment was isolated following electrophoresis
25 through a 4% agarose gel. The third piece of the ligation is a 1.8 kbp DNA fragment of pCFM1156 cut with *NdeI* and *SstI* isolated following electrophoresis through a 1% agarose gel. Following ligation (T4 ligase), transformation, kanamycin selection and DNA
30 sequencing as described above, a clone was picked containing the construct in Figure 4 and the plasmid designated KGF. Because of an internal ribosomal binding site that produced truncated products, the KGF DNA sequence between the unique *KpnI* and *EcoRI* sites
35 was replaced with chemically synthesized OLIGOS

- 32 -

(OLIGO#6 through OLIGO#11) to minimize the use of the internal start site (Figure 5).

OLIGO#1 (SEQ ID NO:7): 5'-CAATGACCTAGGAGTAACAATCAAC-3'

5 OLIGO#2 (SEQ ID NO:8): 5'-AAAACAAACATAAATGCACAAGTCCA-3'

OLIGO#3 (SEQ ID NO:9): 5'-ACAACGCGTGCAATGACATGACTCCA-3'

OLIGO#4 (SEQ ID NO:10):

5'-ACAGGATCCTATTAAGTTATTGCCATAGGAA-3'

OLIGO#5 (SEQ ID NO:11):

10 5'-ACACATATGTGCAATGACATGACTCCA-3'

OLIGO#6 (SEQ ID NO:12):

5'-CTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCC-3'

OLIGO#7 (SEQ ID NO:13):

5'-AAGAGATGAAAAACAACACTACAATATTATGGAAATCCGTACTGTT-3'

15 OLIGO#8 (SEQ ID NO:14):

5'-GCTGTTGGTATCGTTGCAATCAAAGGTGTTGAATCTG-3'

OLIGO#9 (SEQ ID NO:15):

5'-TCTTGGGTGCCCTTGACTTTGCCGCGTTTGTGATACGCAGGTAC-3'

OLIGO#10 (SEQ ID NO:16):

20 5'-ACAGCAACAGTACGGATTCCATAATATTGTAGTTGTTTTTCATC-3'

OLIGO#11 (SEQ ID NO:17):

5'-AATTCAGATTCAACACCTTTGATTGCAACGATACCA-3'

The OLIGOs were phosphorylated with T4

25 polynucleotide kinase and then heat denatured. The single-stranded (ss) OLIGOs were then allowed to form a ds DNA fragment by allowing the temperature to slowly decrease to room temperature. T4 ligase was then used to covalently link both the internal OLIGO sticky-ends

30 and the whole ds OLIGO fragment to the KGF plasmid cut with *KpnI* and *EcoRI*. The new plasmid was designated KGF(dsd).

A completely *E. coli* codon-optimized KGF gene was constructed by PCR amplification of chemically

35 synthesized OLIGOs #12 through 24.

- 33 -

OLIGO#12 (SEQ ID NO:18): 5'-AGTTTGTGATCTAGAAGGAGG-3'

OLIGO#13 (SEQ ID NO:19): 5'-TCAAAACTGGATCCTATTAA-3'

OLIGO#14 (SEQ ID NO:20):

5'-AGTTTGTGATCTAGAAGGAGGAATAACATATGTGCAACGACATG-
ACTCCGGAACAGATGGCTACCAACGTTAAGTCTCCAGCCCGAACGT-3'

OLIGO#15 (SEQ ID NO:21):

5'-CACACCCGTAGCTACGACTACATGGAAGGTGGTGACATCCGT-
GTTTCGTCGTCTGTTCTGCCGTACCCAGTGGTACCTGCGTATCGACAAA-3'

OLIGO#16 (SEQ ID NO:22):

5'-CGTGGTAAAGTTAAAGGTACCCAGGAAATGAAAAACAACCTACAACATC-
ATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAA-3'

OLIGO#17 (SEQ ID NO:23):

5'-GGTGTGAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACT-
GTACGCAAAAAAAGAATGCAACGAAGACTGCAACTTCAAAGAA-3'

OLIGO#18 (SEQ ID NO:24):

5'-CTGATCCTGGAAAACCACTACAACACCTACGCATCTGCTAAATGGAC-
CCACAACGGTGGTGAATGTTCGTTGCTCTGAACCAGAAAGGT-3'

OLIGO#19 (SEQ ID NO:25):

5'-ATCCCGGTTTCGTGGTAAAAAAACCAAAAAAGAACAGAAAACCGCTC-
ACTTCCTGCCGATGGCAATCACTTAATAGGATCCAGTTTGA-3'

OLIGO#20 (SEQ ID NO:26): 5'-TACGGGTGTGACGTTCCGGG-3'

OLIGO#21 (SEQ ID NO:27): 5'-CTTTACCACGTTTGTGCGATA-3'

OLIGO#22 (SEQ ID NO:28): 5'-ATTCAACACCTTTGATTGCA-3'

OLIGO#23 (SEQ ID NO:29): 5'-CCAGGATCAGTTCTTTGAAG-3'

OLIGO#24 (SEQ ID NO:30): 5'-GAACCGGGATACCTTTCTGG-3'

OLIGOs #12 through 24 were designed so that the entire DNA sequence encoding native KGF was represented by OLIGOs from either the "Watson" or the "Crick" strand and upon PCR amplification would produce the desired double-stranded DNA sequence (Figure 6) [PCR#5, Model 9600 thermocycler, Perkin-Elmer Cetus]; 21 cycles, each cycle consisting of 31 seconds at 94°C for denaturation, 31 seconds at 50°C for annealing, and 31 seconds at 73°C for elongation; following the 21 cycles the PCR was finished with a final elongation step of 7

- 34 -

minutes]. After PCR amplification, the DNA fragment was cut with *XbaI* and *BamHI* and the 521 bp fragment ligated into the expression plasmid pCFM1156 cut with the same enzymes. PCR#5 utilized the outside primers (100
5 pmoles/100 μ l rxn) OLIGO#12 and OLIGO#13 and 1 μ l/100 μ l rxn of a KGF template derived by ligation (by T4 ligase) of OLIGO#14 through OLIGO#19 (OLIGO#15 through OLIGO#18 were phosphorylated with T4 polynucleotide kinase) using OLIGO#20 through OLIGO#24 as band-aid oligos (Jayaraman
10 et al. (1992), *Biotechniques*, 12:392) for the ligation. The final construct was designated KGF (codon optimized).

All of the KGF analogs described herein are composed in part from DNA sequences found in KGF(dsd) or
15 KGF(codon optimized), or a combination of the two. The sequences are further modified by the insertion into convenient restriction sites of DNA sequences that encode the particular KGF analog amino acids made utilizing one or more of the above-described techniques
20 for DNA fragment synthesis. Any of the analogs can be generated in their entirety by the above described techniques. However, as a part of the general OLIGO design optimized *E. coli* codons were used where appropriate, although the presence of *E. coli* optimized
25 codons in part or in toto of any of the genes where examined did not significantly increase the yield of protein that could be obtained from cultured bacterial cells. Figures 7 to 24 and 37 to 50 set forth by convenient example particular KGF analog nucleotide and
30 amino acid sequence constructions: C(1,15)S (Figure 7); Δ N3/C(15)S (Figure 8); Δ N3/C(15)- (Figure 9); Δ N8/C(15)S (Figure 10); Δ N8/C(15)- (Figure 11); Δ N15 (Figure 12); Δ N16 (Figure 13); Δ N17 (Figure 14); Δ N18 (Figure 15); Δ N19 (Figure 16); Δ N20 (Figure 17); Δ N21 (Figure 18);
35 Δ N22 (Figure 19); Δ N23 (Figure 20); Δ N24 (Figure 21); C(1,15)S/R(144)E (Figure 22); C(1,15)S/R(144)Q

- 35 -

(Figure 23); Δ N23/R(144)Q (Figure 24); C(1,15,40)S
(Figure 37); C(1,15,102)S (Figure 38); C(1,15,102,106)S
(Figure 39); Δ N23/N(137)E (Figure 40); Δ N23/K(139)E
(Figure 41); Δ N23/K(139)Q (Figure 42); Δ N23/R(144)A
5 (Figure 43); Δ N23/R(144)E (Figure 44); Δ N23/R(144)L
(Figure 45); Δ N23/K(147)E (Figure 46); Δ N23/K(147)Q
(Figure 47); Δ N23/K(153)E (Figure 48); Δ N23/K(153)Q
(Figure 49) and Δ N23/Q(152)E/K(153)E (Figure 50). All
the KGF analog constructions described herein were DNA
10 sequence confirmed.

EXAMPLE 2: Production in *E. coli*

Three different expression plasmids were
15 utilized in the cloning of the KGF analog genes. They
were pCFM1156 (ATCC# 69702), pCFM1656 (ATCC# 69576), and
pCFM3102 (Figures 2A, 2B and 2C, respectively). The
plasmid p3102 can be derived from the plasmid pCFM1656
by making a series of site-directed base changes with
20 PCR overlapping oligo mutagenesis. Starting with the
*Bgl*III site (pCFM1656 plasmid bp # 180) immediately 5' to
the plasmid replication promoter, *P*_{copB}, and proceeding
toward the plasmid replication genes, the base pair
changes are as follows:
25

- 36 -

	pCFM1656 bp #	bp in pCFM1656	bp changed to in pCFM3102
	# 204	T/A	C/G
	# 428	A/T	G/C
	# 509	G/C	A/T
5	# 617	- -	insert two G/C bp
	# 677	G/C	T/A
	# 978	T/A	C/G
	# 992	G/C	A/T
	# 1002	A/T	C/G
10	# 1005	C/G	T/A
	# 1026	A/T	T/A
	# 1045	C/G	T/A
	# 1176	G/C	T/A
	# 1464	G/C	T/A
15	# 2026	G/C	bp deletion
	# 2186	C/G	T/A
	# 2479	A/T	T/A
	# 2498-2501	<u>AGTG</u>	<u>GTCA</u>
20		TCAC	CAGT
	# 2641-2647	<u>TCCGAGC</u>	bp deletion
		AGGCTCG	
25	# 3441	G/C	A/T
	# 3452	G/C	A/T
	# 3649	A/T	T/A
	# 4556	--	insert bps
30		(SEQ ID NO:67) 5'- <u>GAGCTCACTAGTGTCGACCTGCAG</u> -3'	
		(SEQ ID NO:68) 3'-CTCGAGTGATCACAGCTGGACGTC-5'	

As seen above, pCFM1156, pCFM1656 and pCFM3102 are very similar to each other and contain many of the same restriction sites. The plasmids were chosen by convenience, and the vector DNA components can be easily exchanged for purposes of new constructs. The host used for all cloning was *E. coli* strain FM5 (ATCC: 53911) and the transformations were carried out (according to the method of Hanahan (1983), *supra*) or by electroelution with a Gene Pulser™ transfection apparatus (BioRad Laboratories, Inc., Hercules, CA) according to the manufacturer's instructions.

Initially, a small, freshly cultured inoculum of the desired recombinant *E. coli* clone harboring the

- 37 -

desired construct on one of the three pCFM vectors was started by transferring 0.1 mL of a frozen glycerol stock of the appropriate strain into a 2 L flask containing 500 mL of Luria broth. The culture was
5 shaken at 30°C for 16 hours, after which the culture was transferred to a 15 L fermentor containing 8 L of sterile batch medium (Tsai, et al. (1987), *J. Industrial Microbiol.*, 2:181-187).

Feed batch fermentation starts with the
10 feeding of Feed # 1 medium (Tsai, et al. (1987), *supra*). When the OD600 reached 35, expression of the desired KGF analog was induced by rapidly raising the culture temperature to 37°C for two hours then up to 42°C to denature the CI repressor. The addition of Feed
15 1 was discontinued in favor of Feed 2, the addition rate of which was initiated at 300 mL/hr. Feed 2 comprised 175 g/L trypticase-peptone, 87.5 g/L yeast extract, and 260 g/L glucose. After one hour at 42°C, the culture temperature was decreased to 36°C, where this
20 temperature was then maintained for another 6 hours.

The fermentation was then halted and the cells were harvested by centrifugation into plastic bags placed within 1 L centrifuge bottles. The cells were pelleted by centrifugation at 400 rpm for 60 minutes,
25 after which the supernatants were removed and the cell paste frozen at -90°C.

Following expression of the various KGF analogs in *E. coli*, native KGF, C(1,15)S, C(1,15)S/R(144)E, C(1,15)S/R(144)Q, ΔN15, ΔN23, and
30 ΔN23/R(144)Q proteins were purified using the following procedure. Cell paste from a high cell density fermentation was suspended at 4°C in 0.2 M NaCl, 20 mM NaPO₄, pH 7.5 as a 10-20% solution (weight per volume) using a suitable high shear mixer. The suspended cells
35 were then lysed by passing the solution through a homogenizer (APV Gaulin, Inc., Everett, MA) three times.

- 38 -

The outflowing homogenate was cooled to 4-8°C by using a suitable heat exchanger. Debris was then removed by centrifuging the lysate in a J-6B™ centrifuge (Beckman Instruments, Inc., Brea, CA) equipped with a JS 4.2 rotor at 4,200 rpm for 30-60 min. at 4°C. Supernatants were then carefully decanted and loaded onto a previously prepared 450 mL (5 cm x 23 cm) column of S-Sepharose Fast Flow™ resin (Pharmacia, Piscataway, NJ) equilibrated with 0.2 M NaCl, 20 mM NaPO₄, pH 7.5 at 4°C. Next, the column was washed with five column volumes (2250 mL) of 0.4 M NaCl, 20 mM NaPO₄, pH 7.5 at 4°C. The desired protein was eluted by washing the column with 5 L of 0.5 M NaCl, 20 mM NaPO₄, pH 7.5. 50 mL fractions were collected and the A₂₈₀ of the effluent was continuously monitored. Fractions identified by A₂₈₀ as containing eluted material were then analyzed by SDS-PAGE through 14% gels to confirm the presence of the desired polypeptide.

Those fractions containing proteins of interest were then pooled, followed by the addition of an equal volume of distilled water. The diluted sample was then loaded onto a previously prepared a 450 mL (5 cm x 23 cm) column of S-Sepharose Fast Flow equilibrated with 0.4 M NaCl, 20 mM NaPO₄, pH 6.8 at 4°C. The column was washed with 2250 mL of 0.4 M NaCl, 20 mM NaPO₄, pH 6.8 and the protein eluted using a 20 column volume linear gradient ranging from 0.4 M NaCl, 20 mM NaPO₄, pH 6.8 to 0.6 M NaCl, 20 mM NaPO₄, pH 6.8. Again, 50 mL fractions were collected under constant A₂₈₀ monitoring of the effluent. Those fractions containing the protein (determined by 14% SDS-PAGE) were then pooled, followed by concentration through a YM-10 membrane (10,000 molecular weight cutoff) in a 350cc stirring cell (Amicon, Inc. Mayberry, MA) to a volume of 30-40 mL.

- 39 -

The concentrate was then loaded onto a previously generated 1,300 mL (4.4 cm x 85 cm) column of Superdex-75™ resin (Pharmacia) equilibrated in column buffer comprising 1X PBS (Dulbecco's Phosphate Buffered Saline, "D-PBS", calcium and magnesium-free) or 0.15 M NaCl, 20 mM NaPO₄, pH 7.0. After allowing the sample to run into the column, the protein was eluted from the gel filtration matrix using column buffer. Thereafter, 10 mL fractions were recovered and those containing the analog (determined by 14% SDS-PAGE) were pooled. Typically, the protein concentration was about 5-10 mg/mL in the resultant pool. All of the above procedures were performed at 4-8°C, unless otherwise specified.

15 An alternative purification procedure was used to purify native KGF, C(1,15)S and ΔN23. The procedure involves the following steps, and unless otherwise specified, all procedures, solutions and materials were conducted at 23 ± 5°C.

20 Upon completion of the production phase of a bacterial fermentation, the cell culture was cooled to 4-8°C and the cells harvested by centrifugation or a similar process. On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, was suspended in a mild buffer solution of 20 mM NaPO₄, 0.2 M NaCl, pH 7.5, weighing about five times that of the cell paste to be suspended. The cells were dispersed to a homogeneous solution using a high shear mixer. The temperature of the cell paste dispersion was maintained at 4-8°C during homogenization.

35 The cells were then lysed by pressure, for example by passing the cell paste dispersion twice through an appropriately-sized cell homogenizer. The homogenate was kept chilled at 5 ± 3°C. To clarify the

- 40 -

cell lysate, a previously prepared depth filter housing (Cuno, Inc., Meriden, CT) equipped with a filter having an appropriate amount of filter surface area, equilibrated with a suitable volume of 0.2 M NaCl, 20 mM NaPO₄, pH 7.5, was employed. The equilibration and clarification were performed at $5 \pm 3^\circ\text{C}$. Prior to clarification, an appropriate amount of a suitable filter aid was used to pre-coat the filter and be thoroughly mixed with the cell lysate, after which the lysate was clarified by passing the solution through the filter apparatus. The filter was washed with 0.2 M NaCl, 20 mM NaPO₄, pH 7.5. The filtrate and any subsequent wash were collected in a chilled container of suitable capacity, all the while being maintained at less than 10°C .

Following clarification, the lysate was then passed through a previously prepared a column of SP-Sepharose Fast Flow containing at least 1 mL of resin per 2 g of cell paste. The column of SP-Sepharose Fast Flow was equilibrated with cold ($5 \pm 3^\circ\text{C}$), 0.2 M NaCl, 20 mM NaPO₄, pH 7.5. The temperature of the column was maintained at less than 10°C . The clarified lysate ($5 \pm 3^\circ\text{C}$) was then loaded onto the ion exchange column, with the absorbance at 280 nm (A_{280}) of eluate being continuously monitored. After sample loading, the column was washed with cold 0.2 M NaCl, 20 mM NaPO₄, pH 7.5, followed by washing with 0.3 M NaCl, 20 mM NaPO₄, pH 7.5 at $23 \pm 5^\circ\text{C}$.

To elute the desired protein, a linear gradient ranging from 0.2-1 M NaCl, 20 mM NaPO₄, pH 7.5 was used. Bulk product was collected in several fractions on the basis of the A_{280} of the eluate. Following elution, these fractions were pooled and the volume noted.

To oxidize free sulfhydryl groups, an oxidation step was performed. For proteins with altered

- 41 -

cysteine patterns, as compared to native KGF, an oxidizing agent (e.g., cystamine dihydrochloride or another appropriate oxidizing agent, for instance, cystine, oxidized glutathione or divalent copper) was added to a final concentration of 1-20 mM and the pH was adjusted to 7-9.5, with a pH of 9.0 ± 0.3 being preferred when cystamine dihydrochloride was used. The oxidation was conducted at 10-30°C for an appropriate period. For the native KGF protein, oxidation was accomplished by adding an appropriate amount of $(\text{NH}_4)_2\text{SO}_4$ such as 1-2 M $(\text{NH}_4)_2\text{SO}_4$, adjusting the pH to 7.5 ± 9.5 , and holding the temperature at $23 \pm 5^\circ\text{C}$ for an appropriate period.

After oxidation, the pH of the solution was adjusted to between 6.5 and 9.5. If necessary, solid $(\text{NH}_4)_2\text{SO}_4$ was added to the solution to a final concentration of 2 M. To remove particulates, the solution was passed through appropriate clarification filters.

The filtered, oxidized product was then subjected to hydrophobic interaction chromatography (HIC). The HIC matrix was Butyl-650M Toyopearl™ resin (Tosohaas, Inc., Montgomeryville, PA). The protein-containing solution was loaded onto the column, which had been previously equilibrated with 2 M $(\text{NH}_4)_2\text{SO}_4$, 0.15 M NaCl, 20 mM NaPO_4 , pH 7.0. After sample loading, the column was washed with 2 M $(\text{NH}_4)_2\text{SO}_4$, 0.15 M NaCl, 20 mM NaPO_4 , pH 7.0. The desired protein was then eluted using a decreasing linear $(\text{NH}_4)_2\text{SO}_4$ gradient ranging from 2-0 M developed in 0.15 M NaCl, 20 mM NaPO_4 , pH 7.0. When the desired protein began to elute, as indicated by an increase in the A_{280} of the eluate, fractions were collected. Aliquots of each fraction were then analyzed by SDS-PAGE. Those fractions containing the desired protein were then pooled, thoroughly mixed, and the

- 42 -

volume of the pool determined, as was the concentration of the protein therein.

The pooled HIC protein-containing eluate was then concentrated and the elution buffer exchanged.

5 Typically, proteins were concentrated to 5.0-10.0 mg/mL. Ultrafiltration was conducted using an ultrafiltration system equipped with a PTGC Pellicon™ cassette system (Millipore, Inc., Bedford, MA) with an appropriately sized cut-off membrane

10 After concentration, the sample was diafiltered against an appropriate buffer. The retentate from the concentration step was diafiltered against 0.15 M NaCl, 20 mM NaPO₄, pH 7.0 until the conductivity of the retentate was within 5% of the
15 conductivity of the 0.15 M NaCl, 20 mM NaPO₄, pH 7.0 solution.

In addition, to remove precipitates and bacterial endotoxin that might be present, the concentrated diafiltered protein-containing sample was
20 passed through a 0.1 µm Posidyne™ filter (Pall, Inc., Cortland, NY). After determining the protein concentration of the solution and on the basis of the desired concentration of the final bulk product, the solution was diluted with 0.15 M NaCl, 20 mM sodium
25 phosphate, pH 7.0, to the desired final concentration. A final aseptic filtration through a 0.22 µm filter was then performed as the final bulk product was transferred to a pyrogen-free container for storage (at about 5°C) for further formulation.

30

B. Analysis

Analysis was conducted using *E. coli*-derived, native KGF; C(1,15)S; C(1,15)S/R(144)Q; ΔN15; ΔN23 and
35 ΔN23/R(144)Q.

- 43 -

Conformational Stability

The polypeptides were compared by their storage stability, thermal unfolding transition temperatures (T_m), and stability in a broad range of pH conditions.

Storage Stability

10 Native KGF and C(1,15)S were incubated at 37°C for about 24 hrs, and the remaining soluble protein determined. The results are summarized in Figures 24 to 26.

15 Figure 25 compares native KGF and C(1,15)S when stored in 20 mM Na phosphate, 0.15 M NaCl, pH 7.0 at 37°C for 27 hrs. C(1,15)S showed a significantly increased amount of soluble protein relative to native KGF.

20 Figure 26 compares native KGF and C(1,15)S stored in 0.15 M NaCl, 20 mM NaPO₄, 0.15 M NaCl, pH 7.0 when stored at 37°C. Here again, C(1,15)S gave enhanced stability relative to native KGF.

25 Figure 27 compares the stability of native KGF, Δ N15 and C(1,15)S in PBS and in 50 mM NaPO₄, 0.15 M NaCl, pH 7.0, when stored at 37°C for 18 hrs. The recovery of soluble protein is much higher in high phosphate than in PBS (100 vs. 65%). Δ N15 as well as C(1,15)S showed significantly enhanced stability, as compared with native KGF. Δ N15 and C(1,15)S also gave 30 ~100% recovery in high phosphate, as expected from the result of native KGF.

However, a single preliminary comparative example of storage stability was conducted between C(1,15,40)S, and C(40)S (which is encoded by bases 201 35 to 684 of SEQ ID NO:1, except that Ser⁴⁰ is encoded by AGA); and between C(1,15,102), and C(102)S (which is

- 44 -

encoded by bases 201 to 684 of SEQ ID NO:1, except that Ser¹⁰² is encoded by AGG). The results (not shown) indicated a decreased stability (i.e., less soluble protein after being stored at 37° C). However, the amount of soluble, correctly folded C(1,15,40)S protein which was purified from the culture medium was greater than that of C(40)S, suggesting that C(1,15,40)S may in fact be more stable and that the results from the comparative example are inconclusive. The present invention preferably includes a KGF analog having other than substitutions at Cys⁴⁰, Cys¹⁰², Cys¹⁰⁶ and more preferably excludes C(1,15,40)S, C(1,15,102)S and C(1,15,40,102,106)

The ability of C(1,15)S/R(144)Q and ΔN23/R(144)Q to prevent aggregation at elevated temperatures was also examined. Samples containing 0.5 mg/mL of protein were prepared in D-PBS. 0.5 mL of each sample was aliquoted into 3 cc type-1 glass vials. The vials were sealed with rubber stoppers and 13 mm flip-off aluminum seals were crimped on. These vials were then placed in a 37°C incubator. At predetermined time intervals, vials were withdrawn and analyzed for the loss of soluble protein. Visible precipitates were removed by centrifuging 250 µL of each sample through a 0.22 µm Spin-X™ filter unit (Costar, Cambridge, MA). Soluble protein in the filtered solutions was subsequently analyzed by size exclusion HPLC. The amount of soluble protein was determined by integrating the HPLC peak area and plotting the result as a function of incubation time at 37°C. The results are shown in Figure 27.

The half-lives for the loss of soluble, monomeric protein were then estimated from these kinetic curves. Table 1 shows the half-life for remaining soluble KGF upon storage at 37°C for these proteins.

- 45 -

Table 1
Half-life for the Loss of Soluble, Monomeric Proteins

Protein	t _{1/2} (day)
native KGF	0.6
ΔN23	1.1
C(1,15)	1.2
C(1,15)S/R(144)Q	13.3
ΔN23/R144Q	22.3
C(1,15)S/R(144)E	38.0

5 As seen in Table 1, above, and Figure 28, the
native KGF aggregated the most rapidly, with a
solubility half-life of 0.6 days. C(1,15)S/R(144)Q,
ΔN23/R(144)Q and C(1,15)S/R(144)E showed substantial
increases in the solubility half-life to 13.3, 22.3 and
10 38 days, respectively.

Thermal Unfolding

Thermal unfolding was monitored by circular
15 dichroism (CD) at 230 nm using a J-720™
spectropolarimeter (Jasco, Inc., Easton, MD) equipped
with a PTC-343 Peltier-type temperature control system.
For CD analysis, separate samples containing 0.1 mg/mL
of the polypeptide to be analyzed were prepared in D-PBS
20 (Life Technologies, Inc., Grand Island, NY). For each
sample, about 2.5 mL was loaded into a 10 mm path length
rectangular Suprasil™ quartz (Heraeus Quarzschmelze,
GmbH, Hanau, Germany) fluorescent cell (Hellma Cells,
Inc., Jamaica, NY). The cell was then placed into the
25 Peltier-type temperature control system in the
spectropolarimeter. Thermal unfolding was carried out
at a rate of 50°C/hr. Changes in ellipticity were
monitored at 230 nm to indicate unfolding. The T_m of
each sample was estimated by identifying a temperature

- 46 -

at which 50% of protein molecules in the solution were unfolded (*Biophysical Chemistry*, Cantor and Schimmel (eds), W.H. Freeman and Co. San Francisco (1980)). The estimated T_m for each of the three proteins is listed in Table 2.

Table 2
Estimated Melting Temperatures

Protein	T_m (°C)
native KGF	54.0
$\Delta N15$	55.0
C(1,15)S	55.0
$\Delta N23$	56.0
C(1,15)S/R(144)Q	62.5
$\Delta N23/R144Q$	63.0
C(1,15)S/R(144)E	63.5

10

As these results show, C(1,15)S and $\Delta N15$ have a 1°C increase in the T_m as compared with native KGF. The $\Delta N23$ has an additional degree increase in T_m . However, the substitution of R144Q to C(1,15)S/R(144)Q or $\Delta N23$ adds a greater than 6°C increase in T_m and more than 7°C as compared with native KGF. Moreover, C(1,15)S/R(144)E is greater than 9°C more stable than native KGF.

20

pH

The acid stabilities of C(1,15)S/R(144)Q and C(1,15)S/R(144)E were also compared to that of native KGF, by adjusting D-PBS to different pH values by adding concentrated HCl or NaOH. Approximately 2.35 mL of D-PBS at different pH values was mixed with 100 μ L of 2.45 mg/mL KGF protein in a quartz cell. These samples

25

- 47 -

were thermally unfolded at a rate of 50°C/hr and monitored by CD at 230 nm. Figure 29 shows the T_m as a function of pH for native KGF, C(1,15)S/R(144)Q and C(1,15)S/R(144)E. In the pH range tested, the
5 C(1,15)S/R(144)Q and C(1,15)S/R(144)E always have a higher T_m than the native KGF.

In vitro Biological Activity

10 In vitro mitogenic activity of C(1,15)S, Δ N15, Δ N23, Δ N23/R(144)Q, C(1,15)S/R(144)Q and C(1,15)S/R(144)E was also determined as a function of protein concentration and the half-maximal concentrations by measurement of [3 H]-thymidine uptake
15 by Balb/MK cells (according to the methods of Rubin et al. (1989), supra). Generally, the concentrations of each of the KGF analogs relative to a known standard native KGF was determined using an in vitro biological assay. Each KGF analog was then diluted and assayed for
20 biological activity using a Balb/MK mitogenic assay. The samples were first diluted in a bioassay medium consisting of 50% customer-made Eagle's MEM, 50% customer-made F12, 5 μ g/ml transferrin, 5 ng/ml sodium selenite, 0.0005% HSA and 0.005% Tween 20. KGF samples
25 were then added into Falcon primaria 96-well plates seeded with Balb/MK cells. Incorporation of [3 H]-Thymidine during DNA synthesis was measured and converted to input native KGF concentration by comparison to a native KGF standard curve. The results
30 are presented in Figures 30 to 35. As seen in the Figures, the tested KGF analogs described in Figures 29 to 34 have comparable activity to native KGF.

- 48 -

Example 3: Production in Mammalian Cell Culture

This example describes the expression, isolation, and characterization of two biologically active recombinant KGF (rKGF) forms produced in a mammalian expression system.

The human KGF gene was isolated by PCR amplification of cDNA made from normal dermal human fibroblast cells (Clonetec, Inc., San Diego, CA). Following the making of cDNA by reverse transcriptase, PCR was used to amplify the KGF gene. OLIGO#25 and OLIGO#26 were used to amplify the gene out of the cDNA, and OLIGO#27 and OLIGO#28 were used to place *Hind*III and *Bgl*III restriction sites at the fragment ends by a second PCR amplification, as set forth in Figure 1.

OLIGO#25 (SEQ ID NO:69): 5'-CAATCTACAATTCACAGA-3'

OLIGO#26 (SEQ ID NO:70): 5'-TTAAGTTATTGCCATAGG-3'

OLIGO#27 (SEQ ID NO:71): 5'-AACAAAGCTTCTACAATTCACAGATAGGA-3'

OLIGO#28 (SEQ ID NO:72): 5'-AACAAGATCTTAAGTTATTGCCATAGG-3'

Following cloning and DNA sequence confirmation, the KGF gene DNA was then used. Amplification was effected using OLIGO#29 and OLIGO#30.

OLIGO#29 (SEQ ID NO:73):

5'-CGGTCTAGACCACCATGCACAAATGGATACTGACATGG-3'

OLIGO#30 (SEQ ID NO:74):

5'-GCCGTCGACCTATTAAGTTATTGCCATAGGAAG-3'

The sense primer, OLIGO#29, included an *Xba*I site and a consensus Kozak translation sequence (5'-CCACC-3') upstream of the start codon, ATG. The antisense primer, OLIGO#30, included a *Sal*I cloning site and an additional stop codon. After 18 cycles of PCR amplification (30 sec. denaturation at 94°C, 40 sec.

- 49 -

annealing at 55°C, and 40 sec. elongation at 72°C), the product was digested with *Xba*I and *Sal*I and ligated with a similarly digested DNA of pDSR α 2 (according to the methods of Bourdrel et al. (1993), *Protein Exp. & Purif.*, 4:130-140 and Lu et al. (1992), *Arch. Biochem. Biophys.*, 298:150-158). This resulted in plasmid KGF/pDSR α 2 which placed the human KGF gene between the SV40 early promoter and the α -FSH polyadenylation sequences. Two clones were picked and DNA sequence analysis confirmed construction of the desired vector.

Two micrograms of KGF/pDSR α 2 DNA were then linearized with *Pvu*I. Chinese hamster ovary (CHO) cells, seeded the day before at 0.8×10^6 cells/60 mm culture dish, were then transfected with the treated DNA using a standard calcium phosphate precipitation method (Bourdrel et al., *supra*). Two weeks later, individual colonies were picked and transferred into 24-well plates. The conditioned media was considered serum free when the cells reached confluency and aliquots thereof were analyzed by Western blotting using a polyclonal rabbit antiserum reactive against *E. coli*-expressed human KGF.

Westerns were performed by running samples through 12.5% (w/v) SDS polyacrylamide gels, followed by electroblotting for 1 hr. at 400 mA onto nitrocellulose membranes using a semidry transfer apparatus (Hoefer Scientific Instruments, San Francisco, CA). 20 mM Tris, 150 mM glycine, 20% methanol served as the transfer buffer. The nitrocellulose sheets were blocked by incubation with 10% normal goat serum in PBS. Rabbit anti-serum raised against *E. coli*-derived KGF was used as primary antibody. For use, it was diluted 1/10,000 in 1% normal goat serum in PBS and incubated with the blocked nitrocellulose sheets for 12 hr. at room temperature, after which excess antibody was removed by three 30 min. washes in PBS. The nitrocellulose

- 50 -

membranes were then incubated in 100 mL of 1% normal goat serum in PBS containing Vectastain™ biotinylated goat anti-rabbit IgG (secondary antibody, Vector Labs, Burlingame, CA) for 30 minutes at room temperature.

5 After three 10-minute washes in PBS, a 30-minute room temperature incubation was performed in a 100 mL solution of 1% normal goat serum containing streptavidin and biotinylated peroxidase, prepared according to manufacturer's directions (Vector Labs). Following
10 three washes in PBS, KGF cross-reactive material was visualized by incubation in a mixture of 60 µL of 30% (w/v) H₂O₂ in 100 mL of PBS and 50 mg of 4 chloronaphthol in 20 mL of methanol. The reaction was stopped by rinsing in water after 10 minutes.

15 Analysis of the blots revealed that the KGF-specific antibody associated with three distinct protein bands, two being closely related with molecular weights of about 25-29 kDa and one with an estimated molecular weight of about 17 kDa, as compared to the expected
20 molecular weight of approximately 18.8 of the 163 amino acid mature protein. Additionally, several high-expressing clones secreting more than 2.0 mg of rKGF per liter, as judged by Western analysis, were selected and expanded into roller bottles (according to
25 the method of Lu et al., *supra*) to generate large volumes of serum-free conditioned medium for purification of KGF by cationic exchange chromatography and gel filtration, as set forth below.

KGF from 3 L of serum-free conditioned medium
30 was purified applying the medium directly to a cation exchange column (5 x 24 cm) packed with 450 mL of sulfoethyl a column of S-Sepharose Fast Flow (Pharmacia) pre-equilibrated with 20 mM sodium phosphate, pH 7.5. After washing with five column volumes of 20 mM sodium
35 phosphate, 0.2 M NaCl, pH 7.5, rKGF was eluted using a 20-column volume linear gradient of 0.2 to 1.0 M NaCl in

- 51 -

20 mM sodium phosphate, pH 7.5. 50 mL fractions were collected with continuous A₂₈₀ monitoring. KGF protein was detected by analyzing aliquots of each fraction by SDS-PAGE. SDS-PAGE was performed on an electrophoresis system (Novex, San Diego, CA) using precast 14% Tris-glycine precast gels (according to the method of Laemmli (1970) *Nature*, 227:680-685). Samples were mixed with non-reducing SDS sample buffer without heating before loading. The proteins were detected by either Coomassie blue or silver staining. Two late-eluting peaks were seen to contain protein bands corresponding to the 25-29 kDa and 17 kDa bands detected by Western blot. The fractions containing each of these peaks were separately concentrated to a volume of less than 1.0 mL and subjected to gel filtration.

The gel filtrations employed columns of Superdex-75™ resin (HR 10/30, Pharmacia) pre-equilibrated with PBS, pH 7.2, and calibrated with the following known molecular weight standards (BioRad, San Francisco, CA): thyroglobulin (670 kDa), g-globulin (158 kDa), ovalbumin (44 kDa), myoglobin (17 kDa) and vitamin B-12 (1.4 kDa). These purification steps resulted in an approximate 2000-fold purification of rKGF, specifically including a 17 kDa and a 30 kDa material, as estimated by silver staining.

In the instance of the higher molecular weight material, rKGF eluted as a major symmetrical peak (by A₂₈₀) which was called KGF-a. Upon SDS-PAGE analysis of a lesser amount of this material, 3 µg/lane versus 6 µg/lane, two bands with a 1-2 kDa molecular weight difference were resolved. In the instance of the lower molecular weight material, termed KGF-b, gel filtration resulted in a protein preparation having the expected mobility. For both KGF-a and KGF-b, the overall yield after purification was approximately 30-40%.

- 52 -

Amino acid sequences from KGF-a and KGF-b were also analyzed. These analyses were performed on an automatic sequencer (Model 477A or 470A, Applied Biosystems, Inc., Foster City, CA) equipped with a Model
5 120A on-line PTH-amino acid analyzer and a Model 900A data collection system (according to the method of Lu et al. (1991), *J. Biol. Chem.*, 266:8102-8107). Edman sequence analysis of KGF-a revealed a major N-terminal sequence of X₁-N-D-M-T-P-E-Q-M-A-T-N-V-X₂-X₃-S- [SEQ ID
10 NO:75]. A minor sequence starting from the third N-terminal amino acid, aspartic acid, was also present in 1.6% of the total sequenceable protein. X₁, X₂, and X₃ were the unassigned due to the absence of phenylthiohydantoinyl (PTH) amino acid signals during
15 sequence analysis. An N-terminal amino acid sequence of KGF predicted from cDNA sequence indicates that X₁ and X₃ are Cys residues and X₂ is asparagine. The absence of X₁ and X₃ indicates that these cysteines may form disulfide bridges. On the basis of the consensus N-linked
20 glycosylation sequence Asn-X-Ser, the absence of the predicted Asn residue corresponding to X₂ indicates that it is a potential N-linked glycosylation site.

Interestingly, N-terminal sequence analysis of KGF-b revealed an N-terminal amino acid sequence of
25 S-Y-D-Y-M-E-G-G-D-I-R-V- (SEQ ID NO:76), indicating that it is an N-terminally truncated form of KGF that has been proteolytically cleaved at the Arg²³-Ser²⁴ peptide bond.

To further characterize purified KGF-a and
30 KGF-b, the protein was subjected to glycosidases (neuraminidase, O-glycanase, and/or N-glycanase), using known techniques (Sasaki et al. (1987), *J. Biol. Chem.*, 262:12059-12076; Takeuchi et al. (1988), *J. Biol. Chem.*, 263:3657-3663; Zsebo et al. (1990), *Cell*, 63:195-201).
35 These data indicate that KGF-a contains N- and O-linked carbohydrates, although the lower molecular weight form

- 53 -

of KGF-a probably contains only N-linked sugar. Glycosidase treatment did not cause molecular weight reduction for KGF-b, indicating that the molecule is unglycosylated.

5 The glycosylation pattern of KGF-a was further characterized by mass spectroscopy of the endoproteinase Glu-C-generated peptides described above. Elucidation of carbohydrate structure of glycopeptides by the stepped orifice method of mass spectrometric analysis
10 has been successfully applied to other proteins (Huddleston et al. (1993), *Anal. Chem.*, 65:877-884; Carr et al. (1993), *Prot. Sci.*, 2:183-196). As confirmed by the isolation of a non-glycosylated peptide, Thr²² seems to be partially glycosylated. Similar mass
15 spectrometric analysis of Asn¹⁴ suggested microheterogeneity in glycosylation, with bi, tri and tetra-antennary structures with varying degrees of sialylation.

Table 3A summarizes the KGF concentration to
20 stimulate [³H]-thymidine incorporation of keratinocytes at half-maximal rate (according to the method of Rubin et al. (1989), *Supra*). Interaction with the KGF receptor was examined using isolated KGF receptor membrane preparations prepared from Balb/MK mouse
25 epidermal keratinocytes (by the procedure described by Massague (19932), *J. Biol. Chem.*, 258:13614-13620). Specifically, various forms of KGF were diluted with 50 mM Tris-HCl, pH 7.5, containing 0.2% bovine serum albumin so as to range in concentration from 0.8 ng to
30 100 ng per 50 μ L. They were individually incubated with the membrane preparation (75 ng/mL) and ¹²⁵I-labeled *E. coli*-derived KGF (1.5 ng). Receptor binding and competition experiments were performed at 4°C for 16 hr., after which time samples were taken, centrifuged,
35 and washed twice with the above diluent buffer to remove unbound and non-specifically bound, labeled KGF.

- 54 -

Samples were then counted for the remaining radioactivity. Competition curves for receptor binding between KGF samples and labeled KGF were constructed by plotting percent uncompetition versus concentrations of each KGF sample. Table 3B summarizes the KGF concentration needed to achieve 60% uncompetition against the labeled *E. coli* derived KGF, expressed as ng/mL.

10

Table 3A

KGF concentration to stimulate [³H]-thymidine incorporation of keratinocytes at half-maximal rate

Forms	ng/mL
<i>E. coli</i> KGF	10
KGF-a	30
KGF-b	30

15

Table 3B

KGF concentration to compete receptor binding with I¹²⁵-labeled KGF at 60% uncompetition rate

Forms	ng/mL
<i>E. coli</i> KGF	65.8
KGF-a	93.5
KGF-b	89.1

20

As shown in Table 3A, KGF-a and KGF-b stimulate comparable [³H]-thymidine incorporation, with the half-maximal rate being stimulated by approximately 30 ng/ml of either analog. Thus, the truncation does not reduce biological activity of the molecule.

25 However, the two analogs have approximately 3-fold lower activity than the *E. coli*-derived, full-length KGF. As shown in Table 3B, radioreceptor assay uncompetition

- 55 -

experiments indicated that *E. coli*-derived KGF, KGF-a, and KGF-b have similar receptor binding activity.

Example 4: In Vivo Biological Assay of KGF Polypeptides

5 Produced in *E. coli* and Mammalian Cell Culture

 A single subcutaneous dose of KGF has been shown to result in a dose-dependent rise in serum cholesterol in mice within 24 hours. Native KGF, KGF-a,
10 C(1,15)S, Δ N15 and Δ N23 were also evaluated for the ability to raise the serum cholesterol level in a dose-dependent manner.

 Each treatment group contained five female Balb/c mice (18-20 gms) obtained from CRL. The protein
15 was diluted with 0.9% saline to achieve a final injection volume of 100 μ l/mouse. Each mouse was administered a single subcutaneous injection, at the following doses:

- 56 -

Group	Treatment	Dose (mg/kg)
1	Native KGF	0.1
	Native KGF	0.25
	Native KGF	0.5
	Native KGF	1
	Native KGF	5
2	C(1,15)S	0.1
	C(1,15)S	0.25
	C(1,15)S	0.5
	C(1,15)S	1
	C(1,15)S	5
3	Δ N15	0.25
	Δ N15	0.5
	Δ N15	1
	Δ N15	5
4	Δ N23	0.1
	Δ N23	0.5
	Δ N23	1
	Δ N23	5
5	KGF-a	0.01
	KGF-a	0.05
	KGF-a	0.1
	KGF-a	0.5
6	Saline Control	-

Twenty-four hours after injection, the mice were sacrificed and bled via cardiac puncture. Blood samples were processed for the determination of serum cholesterol.

5

- 57 -

As shown in Figure 35, each tested KGF analog was found to raise serum cholesterol in a dose dependent manner. Also, there was no apparent difference in bioactivity between any of the tested KGF analogs.

5

In Vivo Model of Diabetes

Chemically-induced diabetes mellitus models in various animal species have been classically used to study the disease and its treatment. Streptozotocin induces diabetes in the mouse, rat, hamster, dog, and monkey although studies in rats and mice are utilized most. Junod et al., *Proc. Soc. Exp. Bio. Med.* **126**:210-205 (1967); Rerup, *Pharm. Rev.* **22**:485-518 (1970); Rossini et al., *P.N.A.S.* **74**:2485-2489 (1977); and Ar'Rajab and Ahren, *Pancreas* **8**:50-57 (1993). In rats, doses of streptozotocin from 45 to 70 mg/kg as a single intravenous dose induce stable disease. Doses below 45 mg/kg induce a transient disease state which is reversible. Within one day of streptozotocin injection, the hyperglycemic state is induced. Blood insulin levels remain essentially unchanged compared with normal rats; however, the total content of insulin and C-peptide in the pancreas is severely decreased. Rats manifest the classic signs and symptoms of diabetes in humans: increased blood glucose levels (hyperglycemia), glucose in the urine (glucosuria), increased thirst (polydipsia), increased urination (polyuria), increased appetite (hyperphagia).

The studies described in this disclosure were carried out with the streptozotocin-induced diabetes model in Sprague-Dawley rats. Male rats weighing 200 260 grams at study initiation were used. Diabetes was induced by a single intravenous injection of streptozotocin at 50 mg of streptozotocin in sodium citrate buffer per kg of body weight. Non-diabetic

- 58 -

control rats received a single intravenous injection of sodium citrate buffer for control purposes. KGF was administered daily as a subcutaneous injection. The KGF dose was 3 or 5 mg/kg/day, depending upon the experiment.

5 In the first experiment, KGF therapy was initiated two days before diabetes, was induced and continued after the induction of diabetes for a total of eight injections. In the second and third experiments, KGF therapy administered subcutaneously was initiated one day after

10 the induction of diabetes with streptozotocin. In the fourth experiment, a 7 day course of KGF therapy was initiated 7 days after streptozotocin treatment and the animals were then followed for an additional 12 weeks. In all experiments, except for the fourth experiment,

15 blood glucose levels, urine glucose levels and urine volume were used as end points for analysis. Additionally, water intake, urine C-peptide levels, or total pancreatic insulin and C-peptide content were measured in some experiments. In the fourth experiment,

20 the only assessed endpoint was blood glucose. Because a large fraction of insulin is removed from the circulation by the liver, measurement of peripheral insulin concentrations reflect post-hepatic metabolism events rather than insulin secretion from the pancreas.

25 Therefore, measurements of C-peptide are often made and used as a peripheral marker of insulin secretion. C-peptide is produced from the processing of pro-insulin to insulin. Insulin and C-peptide are secreted from the beta cells in equimolar amounts, and only a small amount

30 of C-peptide is extracted by the liver.

This study investigated the effect of rKGF on streptozotocin-induced diabetes in Sprague-Dawley rats. On day 0, groups of rats were exposed to either 45 or 50 mg/kg streptozotocin (STZ). Following these treatments,

35 non-fasting blood glucose levels were monitored daily to assess the severity of the islet injury. On day 5, the

- 59 -

STZ-treated animals were placed into one of two groups (20/group) depending on the magnitude of hyperglycemia. The dividing point was set at a blood glucose level of 300 mg/dl. A group of non STZ-treated animals served as
5 controls. On day 7, 10 animals from each hyperglycemic group were given Δ N23 (3 mg/kg/day) or PBS by subcutaneous injection for 7 days. Blood glucose levels were then monitored daily, every other day, or weekly and are set forth in Figure 51. Note that STZ-treated
10 animals from both groups receiving Δ N23 had significant declines in blood glucose during the Δ N23 dosing period. Importantly, the mean blood glucose drop experienced by the STZ-treated animals from the <300 mg/dl starting blood glucose group stabilized at about 150 mg/dl whereas
15 the blood glucose drop seen in the >300 mg/dl starting blood glucose group was only transient. Note that the day scale is non-linear.

While the present invention has been described above both generally and in terms of preferred
20 embodiments, it is understood that other variations and modifications will occur to those skilled in the art in light of the description above.

- 60 -

WHAT IS CLAIMED IS:

1. A polypeptide analog of a KGF having up to the first 24 N-terminal amino acids modified wherein
5 cysteine residues corresponding to amino acid positions 1 and 15 of the KGF [amino acid positions 32 and 46 of SEQ ID NO:2, (Cys¹ and Cys¹⁵, respectively)] are deleted or substituted with another amino acid.
- 10 2. The polypeptide analog of Claim 1 wherein Cys¹ and Cys¹⁵ are deleted.
3. The polypeptide analog of Claim 1 wherein the first 15 to 24 N-terminal amino acids are truncated.
15
4. The polypeptide analog of Claim 1 wherein Cys¹ is deleted and Cys¹⁵ is substituted with another amino acid.
- 20 5. The polypeptide analog of Claim 1 wherein up to the first fourteen N-terminal amino acids are truncated and Cys¹⁵ is substituted with another amino acid.
- 25 6. The polypeptide analog of Claim 1 wherein Cys¹ and Cys¹⁵ are substituted with another amino acid.
7. The polypeptide analog as in any one of Claims 4, 5 or 6 wherein an amino acid selected from the group
30 consisting of alanine, leucine, and serine is substituted for cysteine.
8. The polypeptide analog according to Claim 7 wherein a serine is substituted for a cysteine.

35

- 61 -

9. The polypeptide analog according to Claim 1 selected from the group consisting of C(1,15)S, NA15, NA16, NA17, NA18, NA19, NA20, NA21, NA22, NA23 and NA24, ΔN3/C(15)S, ΔN3/C(15)-, ΔN8/C(15)S, ΔN8/C(15)-, C(1,15)S/R(144)E, C(1,15)S/R(144)Q and ΔN23/R(144)Q.

10. A pharmaceutical formulation comprising a therapeutically effective amount of a polypeptide analog according to Claim 1 and a pharmaceutically acceptable carrier.

11. A pharmaceutical formulation comprising a therapeutically effective amount of a lyophilized polypeptide analog according to Claim 1.

12. The pharmaceutical formulation of Claim 11 further comprising a pharmaceutically acceptable carrier.

13. A nucleic acid molecule selected from the group consisting of DNA and RNA wherein the nucleic acid molecule encodes a polypeptide analog of a KGF having up to the first 24 N-terminal amino acids modified wherein cysteine residues corresponding to amino acid positions 1 and 15 of KGF [amino acid positions 32 and 46 of SEQ ID NO:2 (Cys¹ and Cys¹⁵, respectively)] are deleted or substituted with another amino acid.

14. The nucleic acid molecule of Claim 13 encoding a polypeptide KGF analog wherein Cys¹ and Cys¹⁵ are deleted.

15. The nucleic acid molecule of Claim 13 encoding a polypeptide KGF analog wherein the first 15-24 N-terminal amino acids are truncated.

- 62 -

16. The nucleic acid molecule of Claim 13 encoding a polypeptide KGF analog wherein Cys¹ is deleted and Cys¹⁵ is substituted with another amino acid.

5 17. The nucleic acid molecule of Claim 13 encoding a polypeptide KGF analog wherein up to the first fourteen N-terminal amino acids are truncated and Cys¹⁵ is substituted with another amino acid.

10 18. The nucleic acid molecule of Claim 13 encoding a polypeptide KGF analog wherein Cys¹ and Cys¹⁵ are substituted with another amino acid.

15 19. The nucleic acid molecule as in any one of Claims 16, 17 or 18 wherein an amino acid selected from the group consisting of alanine, leucine, and serine is substituted for cysteine.

20 20. A nucleic acid molecule according to Claim 19 wherein a codon coding for serine is substituted for a codon coding for cysteine.

25 21. The nucleic acid molecule according to Claim 13 wherein the polypeptide analog is selected from the group consisting of C(1,15)S, NA15, NA16, NA17, NA18, NA19, NA20, NA21, NA22, NA23 and NA24, ΔN3/C(15)S, ΔN3/C(15)-, ΔN8/C(15)S, ΔN8/C(15)- and ΔN23/R(144)Q.

30 22. A biologically functional plasmid or viral vector comprising a nucleic acid molecule according to Claim 13.

35 23. A procaryotic or eucaryotic host cell stably transfected or transformed with a biologically functional vector according to Claim 22.

- 63 -

24. A procaryotic host cell according to Claim 23 that is *E. coli*.

25. A eucaryotic host cell according to Claim 23
5 that is a mammalian cell.

26. A eucaryotic host cell according to Claim 25 that is a Chinese hamster ovary cell.

10 27. A process for the production of a polypeptide analog of KGF, the process comprising growing under suitable nutrient conditions a procaryotic or eucaryotic host cell stably transformed with a nucleic acid molecule according to Claim 13, in a manner allowing
15 expression of the encoded polypeptide analog, and isolating the polypeptide analog so produced.

28. A method of stimulating the production of non-fibroblast epithelial cells comprising contacting such
20 cells with an effective amount of a polypeptide analog of a KGF according to Claim 1.

Figure 1

human KGF (+ signal sequence)

```
|---OLIGO#25-----|           |-----OLIGO#1-----|
5'CAATCTACAATTCACAGA 3'       5'CAATGACCTAGGAGTAACAATCAAC 3'
5'CAATCTACAATTCACAGATAGGAAGAGGTCAATGACCTAGGAGTAACAATCAACTCAAGA-
-----+-----+-----+-----+-----+-----+-----+ 60

-TTCATTTTCATTATGTTATTCATGAACACCCGGAGCACTACACTATAATGCACAAATGGA-
-----+-----+-----+-----+-----+-----+-----+ 120
                                     M H K W I

-TACTGACATGGATCCTGCCAACTTTGCTCTACAGATCATGCTTTCACATTATCTGTCTAG-
-----+-----+-----+-----+-----+-----+-----+ 180
    L T W I L P T L L Y R S C F H I I C L V

-TGGGTACTATATCTTTAGCTTGCAATGACATGACTCCAGAGCAAATGGCTACAAATGTGA-
-----+-----+-----+-----+-----+-----+-----+ 240
    G T I S L A C N D M T P E Q M A T N V N

-ACTGTTCCAGCCCTGAGCGACACACAAGAAGTTATGATTACATGGAAGGAGGGGATATAA-
-----+-----+-----+-----+-----+-----+-----+ 300
    C S S P E R H T R S Y D Y M E G G D I R

-GAGTGAGAAGACTCTTCTGTCTGAACACAGTGGTACCTGAGGATCGATAAAAGAGGCAAAG-
-----+-----+-----+-----+-----+-----+-----+ 360
    V R R L F C R T Q W Y L R I D K R G K V

-TAAAAGGGACCCAAGAGATGAAGAATAATTACAATATCATGGAAATCAGGACAGTGGCAG-
-----+-----+-----+-----+-----+-----+-----+ 420
    K G T Q E M K N N Y N I M E I R T V A V

-TTGAATTGTGGCAATCAAAGGGGTGGAAAGTGAATTCTATCTTGCAATGAACAAGGAAG-
-----+-----+-----+-----+-----+-----+-----+ 480
    G I V A I K G V E S E F Y L A M N K E G

-GAAAACCTCTATGCAAAGAAAGAATGCAATGAAGATTGTAACCTTCAAAGAACTAATTCTGG-
-----+-----+-----+-----+-----+-----+-----+ 540
    K L Y A K K E C N E D C N F K E L I L E

-AAAACCATTACAACACATATGCATCAGCTAAATGGACACACAACGGAGGGGAAATGTTTG-
-----+-----+-----+-----+-----+-----+-----+ 600
    N H Y N T Y A S A K W T H N G G E M F V

-TTGCCTTAAATCAAAAGGGGATTCTCTGTAAGAGGAAAAAAGCAAGAAAGAACAAAAA-
-----+-----+-----+-----+-----+-----+-----+ 660
    A L N Q K G I P V R G K K T K K E Q K T

-CAGCCCCTTTCTTCTCTATGGCAATAACTTAATTGCATATGGTATATAAAGAACCCAGTT
-----+-----+-----+-----+-----+-----+-----+ 720
    A H F L P M A I T *
          3'GGATACCGTTATTGAATT 5'
          |----OLIGO#26----|
```

Figure 1
(continued)

```
-CCAGCAGGGAGATTTCTTTAAGTGGACTGTTTTCTTTCTTCTCAAAATTTTCTTTCCTTT
-----+-----+-----+-----+-----+-----+-----+ 780

-TATTTTTTTAGTAATCAAGAAAGGCTGGAAAACTACTGAAAACTGATCAAGCTGGACTT
-----+-----+-----+-----+-----+-----+-----+ 840
                                     3'ACCTGAA-
                                     |-----

-GTGCATTTATGTTTGTTTTAAG 3'
-----+-----+-----+-----+-----+-----+-----+ 862
-CACGTAAATACAAACAAAA 5'
---OLIGO#2-----|
```

Figure 2




Figure 2
(continued)





Figure 2
(continued)

Figure 2C



RSH-KGF

*Cla*I
*Xba*I
*Nde*I
 5'-ATCGATTTCATTCTAGAAGGAGGAATAACATATGAAAAG-
M
K
K

RSH signal sequence
MluI
 -CGCGCACGTGCTATCGCCATTGCTGTGGCTCTGGCAGTTTTCGCAACTAGTGCACA-3'
 R A R A I A I A V A L A G F A T S A H A -

MluI
5' CGCGTGCAATGACATGACTCCAGAGCAAATGGCTACAAATGTGAACTGTTCCAGCCCTGA- 60
- C N D M T P E Q M A T N V N C S S P E

[illegible][illegible][illegible]

EcoRI

-CAAAGGGGTGGAAGTGAATTCTATCTTGCAATGAACAAGGAAGGAAACTCTATGCAA-

-----+-----+-----+-----+-----+

K G V E S E F Y L A M N K E G K L Y A K 300

BsmI

-GAAAGAATGCAATGAAGATTGTAAGTTCAAAGAACTAATTCTGGAAAACCATTCACAACAC- 360

K E C N E D C N F K E L I L E N H Y N T

NdeI

-ATATGCATCAGCTAAATGGACACACAACGGAGGGGAAATGTTTGTTCCTTAAATCAAAA-

Y A S A K W T H N G G E M F V A L N Q K 420

-GGGGATTCTGTAAAGAGGAAAAAAACGAAGAAAGAACAAAAACAGCCCACTTTCTTCC-
-----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 480
G I P V R G K K T K K E Q K T A H F L P

*Bam*HI

-TATGGCAATAACTTAATAG 3'

-----+-----+----- 503

M A I T * *

-plasmid DNA
-sequence

Figure 4

KGF

NdeI
5' TATGTGCAATGACATGACTCCAGAGCAAATGGCTACAAATGTGAACTGTTCCAGCCCTGA-
-----+-----+-----+-----+-----+-----+ 60
M C N D M T P E Q M A T N V N C S S P E
-GCGACACACAAGAAGTTATGATTACATGGAAGGAGGGGATATAAGAGTGAGAAGACTCTT-
-----+-----+-----+-----+-----+-----+ 120
R H T R S Y D Y M E G G D I R V R R L F
KpnI *ClaI*
-CTGTGCAACACAGTGGTACCTGAGGATCGATAAAAGAGGCAAAGTAAAGGGACCCAAGA-
-----+-----+-----+-----+-----+-----+ 180
C R T Q W Y L R I D K R G K V K G T Q E
-GATGAAGAATAATTACAATATCATGGAAATCAGGACAGTGGCAGTTGGAATTGTGGCAAT-
-----+-----+-----+-----+-----+-----+ 240
M K N N Y N I M E I R T V A V G I V A I
EcoRI
-CAAAGGGGTGGAAAGTGAATTCTATCTTGCAATGAACAAGGAAGGAAACTCTATGCAAA-
-----+-----+-----+-----+-----+-----+ 300
K G V E S E F Y L A M N K E G K L Y A K
BsmI
-GAAAGAATGCAATGAAGATTGTAACCTCAAAGAATAATTCTGGAAAACCATTAACAACAC-
-----+-----+-----+-----+-----+-----+ 360
K E C N E D C N F K E L I L E N H Y N T
NdeI
-ATATGCATCAGCTAAATGGACACACAACGGAGGGGAAATGTTTGTTCCTTAAATCAAAA-
-----+-----+-----+-----+-----+-----+ 420
Y A S A K W T H N G G E M F V A L N Q K
-GGGGATTCTGTGAAGAGGAAAAAAAAACGAAGAAAGAACAAAAACAGCCCACTTTCTTCC-
-----+-----+-----+-----+-----+-----+ 480
G I P V R G K K T K K E Q K T A H F L P
BamHI
-TATGGCAATAACTTAATAG 3'
-----+-----+-----+-----+-----+ 503
M A I T *

Figure 5

substitution of KpnI to EcoRI sequence to make KGF(dsd)

KpnI

```

|-----OLIGO#6-----||-----OLIGO#7-----
5' CTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAACAACACTACAAT-
3' CATGGACGCATAGCTGTTTGCGCCGTTTCAGTTCCCGTGGGTTCTCTACTTTTTGTTGATGTTA-
|-----OLIGO#9-----||-----OLIGO#10-----
- L R I D K R G K V K G T Q E M K N N Y N -

```

EcoRI

```

-----||-----OLIGO#8-----|
5' -ATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTTGAATCTG 3'
3' -TAATACCTTTAGGCATGACAACGACAACCATAGCAACGTTAGTTTCCACAACCTTAGACTTAA 5'
-----||-----OLIGO#11-----|
I M E I R T V A V G I V A I K G V E S E -

```

FIGURE 6

KGF (codon optimized)

XbaI

|-----OLIGO#12-----|
 5'AGTTTTGATCTAGAAAGGAGG 3'
 |-----OLIGO#14-----|
 5'AGTTTTGATCTAGAAAGGAGGAATAACATATGTGCAACGACATGACTCCGGAACAGATGGCT-
 -----|-----OLIGO#15-----|
 -ACCAACGTTAACTGCTCCAGCCCGGAACGTCACACCCGTAGCTACGACTACATGGAAGGTG-
 3' GGCCTTGCAGTGTGGGCAT 5'
 |-----OLIGO#20-----|

-----OLIGO#15-----| |
 -GTGACATCCGTGTTTCGTCTGTTCTGCCGTACCCAGTGGTACCTGCGTATCGACAAACG-
 3' ATAGCTGTTTGC-
 |-----OLIGO#21-----|

-----OLIGO#16-----|
 -TGGTAAAGTTAAAGGTACCCAGGAAATGAAAAACAACACTACAACATCATGGAAATCCGTACT-
 -ACCATTC 5'
 -----|

-----|-----OLIGO#17-----|
 -GTTGCTGTTGGTATCGTTGCAATCAAAGGTGTTGAATCTGAATTCTACCTGGCAATGAACA-
 3' ACGTTAGTTTCCACAACCTTA 5'
 |-----OLIGO#22-----|

-----OLIGO#17-----| |-----|
 -AAGAAGGTAACTGTACGCAAAAAAAGAATGCAACGAAGACTGCAACTTCAAAGAACTGAT-
 3' GAAGTTTCTTGACTA-
 |-----OLIGO#23-----|

-----OLIGO#18-----|
 -CCTGGAAAACCACTACAACACCTACGCATCTGCTAAATGGACCCACAACGGTGGTGAAATG-
 -GGACC 5'
 -----|

-----|-----OLIGO#19-----|
 -TTCGTTGCTCTGAACCAGAAAGGTATCCCGGTTCTGGTAAAAAAACCAAAAAAGAACAGA-
 3' GGTCTTTCCATAGGGCCAAG 5'
 |-----OLIGO#24-----|

-----OLIGO#19-----|
 -AAACCGCTCACTTCCTGCCGATGGCAATCACTTAATAGGATCCAGTTTTGA 3'
 3' AATTATCCTAGGTCAAACT 5'
 |-----OLIGO#13-----|

BamHI

Figure 7

KGF C(1,15)S

5' ATGTCTAATGATATGACTCCGGAACAGATGGCTACCAACGTTAACTCCTCCTCCCCGGAA-
-----+-----+-----+-----+-----+ 60
M S N D M T P E Q M A T N V N S S S P E
-CGTCACACGCGTTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCTGTTC-
-----+-----+-----+-----+-----+ 120
R H T R S Y D Y M E G G D I R V R R L F
-TGCCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAG-
-----+-----+-----+-----+-----+ 180
C R T Q W Y L R I D K R G K V K G T Q E
-ATGAAAAACAACACTACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATC-
-----+-----+-----+-----+-----+ 240
M K N N Y N I M E I R T V A V G I V A I
-AAAGGTGTTGAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAA-
-----+-----+-----+-----+-----+ 300
K G V E S E F Y L A M N K E G K L Y A K
-AAAGAATGCAACGAAGACTGCAACTTCAAAGAAGTATCCTGGAAAACCACTACAACACC-
-----+-----+-----+-----+-----+ 360
K E C N E D C N F K E L I L E N H Y N T
-TACGCATCTGCTAAATGGACCCACAACGGTGGTGAATGTTTCGTTGCTCTGAACCAGAAA-
-----+-----+-----+-----+-----+ 420
Y A S A K W T H N G G E M F V A L N Q K
-GGTATCCCGGTTTCGTGGTAAAAAAACCAAAAAGAACAGAAAACCGCTCACTTCCTGCCG-
-----+-----+-----+-----+-----+ 480
G I P V R G K K T K K E Q K T A H F L P
-ATGGCAATCACTTAA 3'
-----+----- 495
M A I T *

Figure 8

KGF ΔN3/C(15)S

5' ATGACTCCGGAACAGATGGCTACCAACGTAACTCCTCCTCCCGGAACGTCACACGCGT-
-----+-----+-----+-----+-----+-----+-----+ 60
M T P E Q M A T N V N S S S P E R H T R
-TCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACCCAG-
-----+-----+-----+-----+-----+-----+-----+ 120
S Y D Y M E G G D I R V R R L F C R T Q
-TGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAACAAC-
-----+-----+-----+-----+-----+-----+-----+ 180
W Y L R I D K R G K V K G T Q E M K N N
-TACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTTGAA-
-----+-----+-----+-----+-----+-----+-----+ 240
Y N I M E I R T V A V G I V A I K G V E
-TCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAGAATGCAAC-
-----+-----+-----+-----+-----+-----+-----+ 300
S E F Y L A M N K E G K L Y A K K E C N
-GAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCTGCT-
-----+-----+-----+-----+-----+-----+-----+ 360
E D C N F K E L I L E N H Y N T Y A S A
-AAATGGACCCACAACGGTGGTGAAATGTTGCTTCTGAACCAGAAAGGTATCCCGGTT-
-----+-----+-----+-----+-----+-----+-----+ 420
K W T H N G G E M F V A L N Q K G I P V
-CGTGGTAAAAAAACCAAAAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATCACT-
-----+-----+-----+-----+-----+-----+-----+ 480
R G K K T K K E Q K T A H F L P M A I T
-TAA 3'
--- 483
*

Figure 9

KGF ΔN3/C(15)-

5' ATGACTCCGGAACAGATGGCTACCAACGTTAACTCTTCTCCTGAACGTCATACGCGTTCC-
-----+-----+-----+-----+-----+ 60
M T P E Q M A T N V N S S P E R H T R S
-TACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACCCAGTGG-
-----+-----+-----+-----+-----+ 120
Y D Y M E G G D I R V R R L F C R T Q W
-TACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAACAACCTAC-
-----+-----+-----+-----+-----+ 180
Y L R I D K R G K V K G T Q E M K N N Y
-AATATTATGGAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTTGAATCT-
-----+-----+-----+-----+-----+ 240
N I M E I R T V A V G I V A I K G V E S
-GAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGCAACGAA-
-----+-----+-----+-----+-----+ 300
E F Y L A M N K E G K L Y A K K E C N E
-GACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCTGCTAAA-
-----+-----+-----+-----+-----+ 360
D C N F K E L I L E N H Y N T Y A S A K
-TGGACCCACAACGGTGGTGAAATGTTTCGTTGCTCTGAACCAGAAAGGTATCCCGGTTTCGT-
-----+-----+-----+-----+-----+ 420
W T H N G G E M F V A L N Q K G I P V R
-GGTAAAAAAACCAAAAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATCACTTAA 3'
-----+-----+-----+-----+-----+ 480
G K K T K K E Q K T A H F L P M A I T *

Figure 10

KGF ΔN8/C(15)S

5' ATGGCTACTAATGTTAACTCCTCTTCTCCTGAACGTCATACGCGTTCCTACGACTACATG-
-----+-----+-----+-----+-----+ 60
M A T N V N S S S P E R H T R S Y D Y M
-GAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACCCAGTGGTACCTGCGTATC-
-----+-----+-----+-----+-----+ 120
E G G D I R V R R L F C R T Q W Y L R I
-GACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAACAACTACAATATTATGGAA-
-----+-----+-----+-----+-----+ 180
D K R G K V K G T Q E M K N N Y N I M E
-ATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTTGAATCTGAATTCTACCTG-
-----+-----+-----+-----+-----+ 240
I R T V A V G I V A I K G V E S E F Y L
-GCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAGAATGCAACGAAGACTGCAACTTC-
-----+-----+-----+-----+-----+ 300
A M N K E G K L Y A K K E C N E D C N F
-AAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCTGCTAAATGGACCCACAAC-
-----+-----+-----+-----+-----+ 360
K E L I L E N H Y N T Y A S A K W T H N
-GGTGGTGAAATGTTTCGTTGCTCTGAACCAGAAAGGTATCCCGGTTTCGTGGTAAAAAAACC-
-----+-----+-----+-----+-----+ 420
G G E M F V A L N Q K G I P V R G K K T
-AAAAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATCACTTAA 3'
-----+-----+-----+-----+-----+ 468
K K E Q K T A H F L P M A I T *

KGF ΔN8/C15-

5' ATGGCTACTAATGTTAACCTCTTCTCCTGAACGTCATACGCGTTCCTACGATACATGGAA- 60
M A T N V N S S P E R H T R S Y D Y M E
-GGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACCCAGTGGTACCTGCGTATCGAC- 120
G G D I R V R R L F C R T Q W Y L R I D
-AAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAACAACCTACAATATTATGGAAATC- 180
K R G K V K G T Q E M K N N Y N I M E I
-CGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTTGAATCTGAATTCTACCTGGCA- 240
R T V A V G I V A I K G V E S E F Y L A
-ATGAACAAAGAAGGTAACTGTACGCAAAAAAGAATGCAACGAAGACTGCAACTTCAAA- 300
M N K E G K L Y A K K E C N E D C N F K
-GAACTGATCCTGGAAAACCACTACAACACCTACGCATCTGCTAAATGGACCCACAACGGT- 360
E L I L E N H Y N T Y A S A K W T H N G
-GGTGAAATGTTGCTTGCTCTGAACCAGAAAGGTATCCCGGTTGCTGGTAAAAAACCAAA- 420
G E M F V A L N Q K G I P V R G K K T K
-AAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATCACTTAA 3' 465
K E Q K T A H F L P M A I T *

Figure 12

KGF Δ N15

5' ATGTCTTCTCCTGAACGTCATACGCGTTCCTACGACTACATGGAAGGTGGTGACATCCGC-
-----+-----+-----+-----+ 60
M S S P E R H T R S Y D Y M E G G D I R
-GTACGTCGTCTGTTCTGCCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTC-
-----+-----+-----+-----+ 120
V R R L F C R T Q W Y L R I D K R G K V
-AAGGGCACCCAAGAGATGAAAAACAACTACAATATTATGGAAATCCGTA CTGTTGCTGTT-
-----+-----+-----+-----+ 180
K G T Q E M K N N Y N I M E I R T V A V
-GGTATCGTTGCAATCAAAGGTGTTGAATCTGAATTCTACCTGGCAATGAACAAAGAAGGT-
-----+-----+-----+-----+ 240
G I V A I K G V E S E F Y L A M N K E G
-AAACTGTACGCAAAAAAAGAATGCAACGAAGACTGCAACTTCAAAGAACTGATCCTGGAA-
-----+-----+-----+-----+ 300
K L Y A K K E C N E D C N F K E L I L E
-AACCCTACAACACCTACGCATCTGCTAAATGGACCCACAACGGTGGTGAAATGTTTCGTT-
-----+-----+-----+-----+ 360
N H Y N T Y A S A K W T H N G G E M F V
-GCTCTGAACCAGAAAGGTATCCCGGTTCGTGGTAAAAAAACCAAAAAAGAACAGAAAACC-
-----+-----+-----+-----+ 420
A L N Q K G I P V R G K K T K K E Q K T
-GCTCACTTCCTGCCGATGGCAATCACTTAA 3'
-----+-----+ 450
A H F L P M A I T *

Figure 13

KGF Δ N16

5' ATGTCTCCTGAACGTCATACGCGTTCCTACGACTACATGGAAGGTGGTGACATCCGCGTA-
-----+-----+-----+-----+-----+ 60
M S P E R H T R S Y D Y M E G G D I R V
-CGTCGTCTGTTCTGCCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAG-
-----+-----+-----+-----+-----+ 120
R R L F C R T Q W Y L R I D K R G K V K
-GGCACCCAAGAGATGAAAAACAACCTACAATATTATGGAAATCCGTACTGTTGCTGTTGGT-
-----+-----+-----+-----+-----+ 180
G T Q E M K N N Y N I M E I R T V A V G
-ATCGTTGCAATCAAAGGTGTTGAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAA-
-----+-----+-----+-----+-----+ 240
I V A I K G V E S E F Y L A M N K E G K
-CTGTACGCAAAAAAAGAATGCAACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAAAC-
-----+-----+-----+-----+-----+ 300
L Y A K K E C N E D C N F K E L I L E N
-CACTACAACACCTACGCATCTGCTAAATGGACCCACAACGGTGGTGAATGTTTCGTTGCT-
-----+-----+-----+-----+-----+ 360
H Y N T Y A S A K W T H N G G E M F V A
-CTGAACCAGAAAGGTATCCCGGTTTCGTGGTAAAAAAACCAAAAAAGAACAGAAAACCGCT-
-----+-----+-----+-----+-----+ 420
L N Q K G I P V R G K K T K K E Q K T A
-CACTTCCTGCCGATGGCAATCACTTAA 3'
-----+-----+-----+-----+-----+ 447
H F L P M A I T *

Figure 14

KGF ΔN17

5'ATGCCTGAACGTCATACGCGTTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGT-
-----+-----+-----+-----+-----+-----+ 60
M P E R H T R S Y D Y M E G G D I R V R
-CGTCTGTTCTGCCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGC-
-----+-----+-----+-----+-----+-----+ 120
R L F C R T Q W Y L R I D K R G K V K G
-ACCCAAGAGATGAAAAACAAC TACAATATTATGGAATCCGTACTGTTGCTGTTGGTATC-
-----+-----+-----+-----+-----+-----+ 180
T Q E M K N N Y N I M E I R T V A V G I
-GTTGCAATCAAAGGTGTTGAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTG-
-----+-----+-----+-----+-----+-----+ 240
V A I K G V E S E F Y L A M N K E G K L
-TACGCAAAAAAGAATGCAACGAAGACTGCAACTTCAAAGAAGTATCCTGGAAAACCAC-
-----+-----+-----+-----+-----+-----+ 300
Y A K K E C N E D C N F K E L I L E N H
-TACAACACCTACGCATCTGCTAAATGGACCCACAACGGTGGTGAAATGTTGCTTGCTCTG-
-----+-----+-----+-----+-----+-----+ 360
Y N T Y A S A K W T H N G G E M F V A L
-AACCAGAAAGGTATCCCGGTTTCGTGGTAAAAAAACCAAAAAAGAACAGAAAACCGCTCAC-
-----+-----+-----+-----+-----+-----+ 420
N Q K G I P V R G K K T K K E Q K T A H
-TTCCTGCCGATGGCAATCACTTAA 3'
-----+-----+-----+-----+-----+ 444
F L P M A I T *

Figure 15

KGF Δ N18

5' ATGGAACGTCATACGCGTTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGT-
-----+-----+-----+-----+-----+ 60
M E R H T R S Y D Y M E G G D I R V R R
-CTGTTCTGCCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACC-
-----+-----+-----+-----+-----+ 120
L F C R T Q W Y L R I D K R G K V K G T
-CAAGAGATGAAAAACAAC TACAATATTATGGAATCCGTACTGTTGCTGTTGGTATCGTT-
-----+-----+-----+-----+-----+ 180
Q E M K N N Y N I M E I R T V A V G I V
-GCAATCAAAGGTGTTGAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTAC-
-----+-----+-----+-----+-----+ 240
A I K G V E S E F Y L A M N K E G K L Y
-GCAAAAAAAGAATGCAACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTAC-
-----+-----+-----+-----+-----+ 300
A K K E C N E D C N F K E L I L E N H Y
-AACACCTACGCATCTGCTAAATGGACCCACAACGGTGGTGAAATGTTTCGTTGCTCTGAAC-
-----+-----+-----+-----+-----+ 360
N T Y A S A K W T H N G G E M F V A L N
-CAGAAAGGTATCCCGGTTTCGTGGTAAAAAAACCAAAAAAGAACAGAAAACCGCTCACTTC-
-----+-----+-----+-----+-----+ 420
Q K G I P V R G K K T K K E Q K T A H F
-CTGCCGATGGCAATCACTTAA 3'
-----+-----+-----+-----+ 441
L P M A I T *

Figure 16

KGF Δ N19

5' ATGCGTCATACGCGTTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTG-
-----+-----+-----+-----+-----+ 60
M R H T R S Y D Y M E G G D I R V R R L
-TTCTGCCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAA-
-----+-----+-----+-----+-----+ 120
F C R T Q W Y L R I D K R G K V K G T Q
-GAGATGAAAAACAACTACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCA-
-----+-----+-----+-----+-----+ 180
E M K N N Y N I M E I R T V A V G I V A
-ATCAAAGGTGTTGAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCA-
-----+-----+-----+-----+-----+ 240
I K G V E S E F Y L A M N K E G K L Y A
-AAAAAGAATGCAACGAAGACTGCAACTTCAAAGAAGTATCCTGGAAAACCACTACAAC-
-----+-----+-----+-----+-----+ 300
K K E C N E D C N F K E L I L E N H Y N
-ACCTACGCATCTGCTAAATGGACCCACAACGGTGGTGAAATGTTTCGTTGCTCTGAACCAG-
-----+-----+-----+-----+-----+ 360
T Y A S A K W T H N G G E M F V A L N Q
-AAAGGTATCCCGGTTTCGTGGTAAAAAAACCAAAAAGAACAGAAAACCGCTCACTTCCTG-
-----+-----+-----+-----+-----+ 420
K G I P V R G K K T K K E Q K T A H F L
-CCGATGGCAATCACTTAA 3'
-----+----- 438
P M A I T *

Figure 17

KGF ΔN20

5' ATGCATACTCGTTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTC-
-----+-----+-----+-----+-----+-----+ 60
M H T R S Y D Y M E G G D I R V R R L F
-TGCCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAG-
-----+-----+-----+-----+-----+-----+ 120
C R T Q W Y L R I D K R G K V K G T Q E
-ATGAAAAACAAC TACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATC-
-----+-----+-----+-----+-----+-----+ 180
M K N N Y N I M E I R T V A V G I V A I
-AAAGGTGTTGAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAA-
-----+-----+-----+-----+-----+-----+ 240
K G V E S E F Y L A M N K E G K L Y A K
-AAAGAATGCAACGAAGACTGCAACTTCAAAGAAGTATCCTGGAAAACCACTACAACACC-
-----+-----+-----+-----+-----+-----+ 300
K E C N E D C N F K E L I L E N H Y N T
-TACGCATCTGCTAAATGGACCCACAACGGTGGTGAAATGTTTCGTTGCTCTGAACCAGAAA-
-----+-----+-----+-----+-----+-----+ 360
Y A S A K W T H N G G E M F V A L N Q K
-GGTATCCCGGTTTCGTGGTAAAAAAACCAAAAAAGAACAGAAAACCGCTCACTTCCTGCCG-
-----+-----+-----+-----+-----+-----+ 420
G I P V R G K K T K K E Q K T A H F L P
-ATGGCAATCACTTAA 3'
-----+----- 435
M A I T *

Figure 18

KGF ΔN21

5'ATGACTCGTTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCTGTTCTGC-
-----+-----+-----+-----+-----+-----+ 60
M T R S Y D Y M E G G D I R V R R L F C
-CGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATG-
-----+-----+-----+-----+-----+-----+ 120
R T Q W Y L R I D K R G K V K G T Q E M
-AAAAACAACACTACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAA-
-----+-----+-----+-----+-----+-----+ 180
K N N Y N I M E I R T V A V G I V A I K
-GGTGTGGAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAA-
-----+-----+-----+-----+-----+-----+ 240
G V E S E F Y L A M N K E G K L Y A K K
-GAATGCAACGAAGACTGCAACTTCAAAGAAGTATCCTGGAAAACCACTACAACACCTAC-
-----+-----+-----+-----+-----+-----+ 300
E C N E D C N F K E L I L E N H Y N T Y
-GCATCTGCTAAATGGACCCACAACGGTGGTGAAATGTTTCGTTGCTCTGAACCAGAAAGGT-
-----+-----+-----+-----+-----+-----+ 360
A S A K W T H N G G E M F V A L N Q K G
-ATCCCGGTTTCGTGGTAAAAAAACCAAAAAAGAACAGAAAACCGCTCACTTCCTGCCGATG-
-----+-----+-----+-----+-----+-----+ 420
I P V R G K K T K K E Q K T A H F L P M
-GCAATCACTTAA 3'
-----+--- 432
A I T *

Figure 19

KGF ΔN22

5' ATGCGTTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGT- 60
-----+-----+-----+-----+-----+
M R S Y D Y M E G G D I R V R R L F C R
-ACCCAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAA- 120
-----+-----+-----+-----+-----+
T Q W Y L R I D K R G K V K G T Q E M K
-AACAACTACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGT- 180
-----+-----+-----+-----+-----+
N N Y N I M E I R T V A V G I V A I K G
-GTTGAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCCAAAAAAGAA- 240
-----+-----+-----+-----+-----+
V E S E F Y L A M N K E G K L Y A K K E
-TGCAACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCA- 300
-----+-----+-----+-----+-----+
C N E D C N F K E L I L E N H Y N T Y A
-TCTGCTAAATGGACCCACAACGGTGGTGAAATGTTGCTTGCTCTGAACCAGAAAGGTATC- 360
-----+-----+-----+-----+-----+
S A K W T H N G G E M F V A L N Q K G I
-CCGGTTCGTGGTAAAAAAACCAAAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCA- 420
-----+-----+-----+-----+-----+
P V R G K K T K K E Q K T A H F L P M A
-ATCACTTAA 3'
----- 429
I T *

Figure 20

KGF ΔN23

5' ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC-
-----+-----+-----+-----+-----+-----+-----+-----+ 60
M S Y D Y M E G G D I R V R R L F C R T
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC-
-----+-----+-----+-----+-----+-----+-----+-----+ 120
Q W Y L R I D K R G K V K G T Q E M K N
-AACTACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT-
-----+-----+-----+-----+-----+-----+-----+-----+ 180
N Y N I M E I R T V A V G I V A I K G V
-GAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGC-
-----+-----+-----+-----+-----+-----+-----+-----+ 240
E S E F Y L A M N K E G K L Y A K K E C
-AACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCT-
-----+-----+-----+-----+-----+-----+-----+-----+ 300
N E D C N F K E L I L E N H Y N T Y A S
-GCTAAATGGACCCACAACGGTGGTGAAATGTTTCGTTGCTCTGAACCAGAAAGGTATCCCG -
-----+-----+-----+-----+-----+-----+-----+-----+ 360
A K W T H N G G E M F V A L N Q K G I P
-GTTTCGTGGTAAAAAAACCAAAAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATC-
-----+-----+-----+-----+-----+-----+-----+-----+ 420
V R G K K T K K E Q K T A H F L P M A I
-ACTTAA 3'
----- 426
T *

Figure 21

KGF ΔN24

5' ATGTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACCCAG-
-----+-----+-----+-----+-----+-----+-----+ 60
M Y D Y M E G G D I R V R R L F C R T Q
-TGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAACAAC-
-----+-----+-----+-----+-----+-----+-----+ 120
W Y L R I D K R G K V K G T Q E M K N N
-TACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTTGAA-
-----+-----+-----+-----+-----+-----+-----+ 180
Y N I M E I R T V A V G I V A I K G V E
-TCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAGAATGCAAC-
-----+-----+-----+-----+-----+-----+-----+ 240
S E F Y L A M N K E G K L Y A K K E C N
-GAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCTGCT-
-----+-----+-----+-----+-----+-----+-----+ 300
E D C N F K E L I L E N H Y N T Y A S A
-AAATGGACCCACAACGGTGGTGAAATGTTGCTTCTGAACCAGAAAGGTATCCCGGTT-
-----+-----+-----+-----+-----+-----+-----+ 360
K W T H N G G E M F V A L N Q K G I P V
-CGTGGTAAAAAAACCAAAAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATCACT-
-----+-----+-----+-----+-----+-----+-----+ 420
R G K K T K K E Q K T A H F L P M A I T
-TAA 3'
--- 423
*

Figure 22

C(1,15)S/R(144)E

5' ATGTCTAATGATATGACTCCGGAACAGATGGCTACCAACGTTAACTCCTCCTCCCCGGAA-
-----+-----+-----+-----+-----+ 60
M S N D M T P E Q M A T N V N S S S P E
-CGTCACACGCGTTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTC-
-----+-----+-----+-----+-----+ 120
R H T R S Y D Y M E G G D I R V R R L F
-TGCCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAG-
-----+-----+-----+-----+-----+ 180
C R T Q W Y L R I D K R G K V K G T Q E
-ATGAAAAACAAC TACAATATTATGGAATCCGTACTGTTGCTGTTGGTATCGTTGCAATC-
-----+-----+-----+-----+-----+ 240
M K N N Y N I M E I R T V A V G I V A I
-AAAGGTGTTGAATCTGAATTCTATCTTGCAATGAACAAGGAAGGAAAAC TCTATGCAAAG-
-----+-----+-----+-----+-----+ 300
K G V E S E F Y L A M N K E G K L Y A K
-AAAGAATGCAATGAAGATTGTAAC TTCAAAGAACTAATTCTGGAAAACCATTACAACACA-
-----+-----+-----+-----+-----+ 360
K E C N E D C N F K E L I L E N H Y N T
-TATGCATCTGCTAAATGGACCCACAACGGTGGTGAAATGTTGCTTGCTCTGAACCAGAAA-
-----+-----+-----+-----+-----+ 420
Y A S A K W T H N G G E M F V A L N Q K
-GGTATCCCTGTTGAAGGTAAGAAAACCAAGAAAGAACAGAAAACCGCTCACTTCCTGCCG-
-----+-----+-----+-----+-----+ 480
G I P V E G K K T K K E Q K T A H F L P
-ATGGCAATCACTTAA 3'
-----+----- 495
M A I T *

Figure 23

KGF C(1,15)S/R(144)Q

5' ATGTCTAATGATATGACTCCGGAACAGATGGCTACCAACGTTAACTCCTCCTCCCCGGAA- 60
-----+-----+-----+-----+-----+
M S N D M T P E Q M A T N V N S S S P E
-CGTCACACGCGTTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTC- 120
-----+-----+-----+-----+-----+
R H T R S Y D Y M E G G D I R V R R L F
-TGCCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAG- 180
-----+-----+-----+-----+-----+
C R T Q W Y L R I D K R G K V K G T Q E
-ATGAAAAACAAC TACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATC- 240
-----+-----+-----+-----+-----+
M K N N Y N I M E I R T V A V G I V A I
-AAAGGTGTTGAATCTGAATTCTATCTTGCAATGAACAAGGAAGGAAAAC TCTATGCAAAG- 300
-----+-----+-----+-----+-----+
K G V E S E F Y L A M N K E G K L Y A K
-AAAGAATGCAATGAAGATTGTAAC TTCAAAGAACTAATTCTGGAAAACCAT TACAACACA- 360
-----+-----+-----+-----+-----+
K E C N E D C N F K E L I L E N H Y N T
-TATGCATCTGCTAAATGGACCCACAACGGTGGTGAAATGTTGCTTGCTCTGAACCAGAAA- 420
-----+-----+-----+-----+-----+
Y A S A K W T H N G G E M F V A L N Q K
-GGTATCCCTGTTCAAGGTAAGAAAACCAAGAAAGAACAGAAAACCGCTCACTTCCTGCCG- 480
-----+-----+-----+-----+-----+
G I P V Q G K K T K K E Q K T A H F L P
-ATGGCAATCACTTAA 3' 495
-----+-----
M A I T *

Figure 24

KGF ΔN23/R(144)Q

5' ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC-
-----+-----+-----+-----+-----+-----+-----+ 60
M S Y D Y M E G G D I R V R R L F C R T
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC-
-----+-----+-----+-----+-----+-----+-----+ 120
Q W Y L R I D K R G K V K G T Q E M K N
-AACTACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT-
-----+-----+-----+-----+-----+-----+-----+ 180
N Y N I M E I R T V A V G I V A I K G V
-GAATCTGAATTCTATCTTGCAATGAACAAGGAAGGAAAACCTCTATGCAAAGAAAGAATGC-
-----+-----+-----+-----+-----+-----+-----+ 240
E S E F Y L A M N K E G K L Y A K K E C-
-AATGAAGATTGTAAC TTCAAAGAACTAATTCTGGAAAACCATTACAACACATATGCATCT-
-----+-----+-----+-----+-----+-----+-----+ 300
N E D C N F K E L I L E N H Y N T Y A S
-GCTAAATGGACCCACAACGGTGGTGAAATGTTGCTGCTCTGAACCAGAAAGGTATCCCT-
-----+-----+-----+-----+-----+-----+-----+ 360
A K W T H N G G E M F V A L N Q K G I P
-GTTCAAGGTAAGAAAACCAAGAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATC-
-----+-----+-----+-----+-----+-----+-----+ 420
V Q G K K T K K E Q K T A H F L P M A I
-ACTTAA 3'
----- 426
T *

Figure 25




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31




Figure 32




Figure 33




Figure 34




Figure 35




Figure 36

Effect of KGF on Serum Cholesterol




Figure 37

KGF C1,15,40S

1 CTAGAAGGAGGAATAACATATGTCTAATGATATGACTCCGGAACAGATGGCTACCAACGT 60
-----+-----+-----+-----+-----+-----+
TTCCTCCTTATTGTATACAGATTACTATACTGAGGCCTTGTCTACCGATGGTTGCA
M S N D M T P E Q M A T N V

61 TAACTCCTCCTCCCCGGAACGTCACACGCGTTCCTACGACTACATGGAAGGTGGTGACAT 120
-----+-----+-----+-----+-----+-----+
ATTGAGGAGGAGGGCCTTGCA GTGTGCGCAAGGATGCTGATGTACCTTCCACCACTGTA
N S S S P E R H T R S Y D Y M E G G D I

121 CCGCGTACGCCGTTTGTCTCTCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAA 180
-----+-----+-----+-----+-----+-----+
GGCGCATGCGGCAAACAAGAGAGCATGGGTCAACATGGACGCATAGCTGTTTGCGCCGTT
R V R R L F S R T Q W Y L R I D K R G K

181 AGTCAAGGGCACCCAAGAGATGAAAAACAAC TACAATATTATGGAAATCCGTACTGTTGC 240
-----+-----+-----+-----+-----+-----+
TCAGTTCCCGTGGGTCTCTACTTTTTGTTGATGTTATAATACCTTTAGGCATGACAACG
V K G T Q E M K N N Y N I M E I R T V A

241 TGTTGGTATCGTTGCAATCAAAGGTGTTGAATCTGAATTCTATCTTGCAATGAACAAGGA 300
-----+-----+-----+-----+-----+-----+
ACAACCATAGCAACGTTAGTTTCCACAAC TTAGACTTAAGATAGAACGTTACTTGTTCCT
V G I V A I K G V E S E F Y L A M N K E

301 AGGAAAAC TCTATGCAAAGAAAGAAATGCAATGAAGATTGTAAC TTCAAAGAACTAATTCT 360
-----+-----+-----+-----+-----+-----+
TCCTTTTGAGATACGTTTCTTTCTTACGTTACTTCTAACATTGAAGTTTCTTGATTAAGA
G K L Y A K K E C N E D C N F K E L I L

361 GGAAAACCAT TACAACACATATGCATCAGCTAAATGGACACACAACGGAGGGGAAATGTT 420
-----+-----+-----+-----+-----+-----+
CCTTTTGGAATGTTGTGTATACGTAGTCGATTTACCTGTGTGTTGCCTCCCCTTTACAA
E N H Y N T Y A S A K W T H N G G E M F

421 TGTTGCCTTAAATCAAAGGGGATTCTGTAAAGAGGAAAAAAAAACGAAGAAAGAACAAAA 480
-----+-----+-----+-----+-----+-----+
ACAACGGAATTTAGTTTTCCCCTAAGGACATTCTCCTTTTTTTTGCTTCTTTCTTGTTTT
V A L N Q K G I P V R G K K T K K E Q K

481 AACAGCCCACTTTCTTCCTATGGCAATAACTTAATAG 521
-----+-----+-----+-----+-----+-----+
TTGTGCGGTGAAAGAAGGATACCGTTATTGAATTATCCTAG
T A H F L P M A I T * *

Figure 38

KGF C1,15,102S

1 CTAGAAGGAGGAATAACATATGTCTAATGATATGACTCCGGAACAGATGGCTACCAACGT 60
-----+-----+-----+-----+-----+
TTCCTCCTTATTGTATACAGATTACTATACTGAGGCCTTGTCTACCGATGGTTGCA
M S N D M T P E Q M A T N V

61 TAACTCCTCCTCCCCGGAACGTCACACGCGTTCCCTACGACTACATGGAAGGTGGTGACAT 120
-----+-----+-----+-----+-----+
ATTGAGGAGGAGGGCCTTGCAGTGTGCGCAAGGATGCTGATGTACCTTCCACCACTGTA
N S S S P E R H T R S Y D Y M E G G D I

121 CCGCGTACGTCGTCTGTTCTGCCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAA 180
-----+-----+-----+-----+-----+
GGCGCATGCAGCAGACAAGACGGCATGGGTACCATGGACGCATAGCTGTTTGCGCCGTT
R V R R L F C R T Q W Y L R I D K R G K

181 AGTCAAGGGCACCCAAGAGATGAAAAACAAC TACAATATTATGGAAATCCGTACTGTTGC 240
-----+-----+-----+-----+-----+
TCAGTTCCCGTGGGTTCTCTACTTTTTGTTGATGTTATAATACCTTTAGGCATGACAACG
V K G T Q E M K N N Y N I M E I R T V A

241 TGTTGGTATCGTTGCAATCAAAGGTGTTGAATCTGAATTCTACCTGGCTATGAACAAAGA 300
-----+-----+-----+-----+-----+
ACAACCATAGCAACGTTAGTTTCCACAACCTTAGACTTAAGATGGACCGATACTTGTTTCT
V G I V A I K G V E S E F Y L A M N K E

301 AGGTAAACTGTACGCTAAAAAAGAATCCAATGAAGATTGTAACCTCAAAGAACTAATTCT 360
-----+-----+-----+-----+-----+
TCCATTTGACATGCGATTTTTTCTTAGGTTACTTCTAACATTGAAGTTTCTTGATTAAGA
G K L Y A K K E S N E D C N F K E L I L

361 GGAAAACCATTAACAACACATATGCATCAGCTAAATGGACACACAACGGAGGGGAAATGTT 420
-----+-----+-----+-----+-----+
CCTTTTGGTAATGTTGTGTATACGTAGTCGATTTACCTGTGTGTTGCCTCCCCTTTACAA
E N H Y N T Y A S A K W T H N G G E M F

421 TGTTGCCTTAAATCAAAGGGGATTCTGTAAAGAGGAAAAAAACGAAGAAAGAACAAAA 480
-----+-----+-----+-----+-----+
ACAACGGAATTTAGTTTTTCCCCTAAGGACATTCTCCTTTTTTTTGCTTCTTTCTTGTTTT
V A L N Q K G I P V R G K K T K K E Q K

481 AACAGCCCCTTTCTTCCTATGGCAATAACTTAATAG 521
-----+-----+-----+-----+
TTGTCGGGTGAAAGAAGGATACCGTTATTGAATTATCCTAG
T A H F L P M A I T * *

Figure 39

KGF C1,15,102,106S

1 CTAGAAGGAGGAATAACATATGTCTAATGATATGACTCCGGAACAGATGGCTACCAACGT 60
-----+-----+-----+-----+-----+
TTCCTCCTTATTGTATACAGATTACTATACTGAGGCCTTGTCTACCGATGGTTGCA
M S N D M T P E Q M A T N V

61 TAACTCCTCCTCCCCGGAACGTCACACGCGTTCCTACGACTACATGGAAGGTGGTGACAT 120
-----+-----+-----+-----+-----+
ATTGAGGAGGAGGGGCCTTGCAGTGTGCGCAAGGATGCTGATGTACCTTCCACCACTGTA
N S S S P E R H T R S Y D Y M E G G D I

121 CCGCGTACGTCGTCTGTTCTGCCGTACCCAGTGGTACCTGCGTATCGACAAACGCGGCAA 180
-----+-----+-----+-----+-----+
GGCGCATGCAGCAGACAAGACGGCATGGGTACCATGGACGCATAGCTGTTTGCGCCGTT
R V R R L F C R T Q W Y L R I D K R G K

181 AGTCAAGGGCACCCAAGAGATGAAAAACAAC TACAATATTATGGAAATCCGTA CTGTTGC 240
-----+-----+-----+-----+-----+
TCAGTTCCCGTGGGTTCTCTACTTTTTGTTGATGTTATAATACCTTTAGGCATGACAACG
V K G T Q E M K N N Y N I M E I R T V A

241 TGTGTTGATCGTTGCAATCAAAGGTGTTGAATCTGAATTCTACCTGGCTATGAACAAAGA 300
-----+-----+-----+-----+-----+
ACAACCATAGCAACGTTAGTTTCCACAACCTTAGACTTAAGATGGACCGATACTTGTTTCT
V G I V A I K G V E S E F Y L A M N K E

301 AGGTAAACTGTACGCTAAAAAAGAATCCAATGAAGATTCTAACTTCAAAGAACTAATTCT 360
-----+-----+-----+-----+-----+
TCCATTTGACATGCGATTTTTTCTTAGGTTACTTCTAAGATTGAAGTTTCTTGATTAAGA
G K L Y A K K E S N E D S N F K E L I L

361 GGAAAACCATTAACAACACATATGCATCAGCTAAATGGACACACAACGGAGGGGAAATGTT 420
-----+-----+-----+-----+-----+
CCTTTTGGTAATGTTGTGTATACGTAGTCGATTTACCTGTGTGTTGCCTCCCCTTTACAA
E N H Y N T Y A S A K W T H N G G E M F

421 TGTGCTTAAATCAAAGGGGATTCTGTAAAGAGGAAAAAAACGAAGAAAGAACAAAA 480
-----+-----+-----+-----+-----+
ACAACGGAATTTAGTTTTTCCCCTAAGGACATTCTCCTTTTTTTTGCTTCTTCTTGT
V A L N Q K G I P V R G K K T K K E Q K

481 AACAGCCCCTTTCTTCTATGGCAATAACTTAATAG 521
-----+-----+-----+-----+-----+
TTGTCGGGTGAAAGAAGGATACCGTTATTGAATTATCCTAG
T A H F L P M A I T * *

Figure 40

 Δ N23/N(137)E

5' -ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC -
+-----+-----+-----+-----+-----+-----+-----+-----+
M S Y D Y M E G G D I R V R R L F C R T -
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC -
+-----+-----+-----+-----+-----+-----+-----+-----+
Q W Y L R I D K R G K V K G T Q E M K N -
-AACTACAATATTATGGAAATCCGTA CTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT -
+-----+-----+-----+-----+-----+-----+-----+-----+
N Y N I M E I R T V A V G I V A I K G V -
-GAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGC -
+-----+-----+-----+-----+-----+-----+-----+-----+
E S E F Y L A M N K E G K L Y A K K E C -
-AACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCT -
+-----+-----+-----+-----+-----+-----+-----+-----+
N E D C N F K E L I L E N H Y N T Y A S -
-GCTAAATGGACCCACAACGGTGGTGAAATGTTTCGTTGCTCTGGAACAGAAAGGTATCCCT -
+-----+-----+-----+-----+-----+-----+-----+-----+
A K W T H N G G E M F V A L E Q K G I P -
-GTTCGTGGTAAGAAAACCAAGAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATC -
+-----+-----+-----+-----+-----+-----+-----+-----+
V R G K K T K K E Q K T A H F L P M A I -
-ACTTAA-3'
+-----
T *

Figure 41

 Δ N23/K(139)E

5' -ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC-
+-----+-----+-----+-----+-----+-----+-----+-----+
M S Y D Y M E G G D I R V R R L F C R T -
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC
+-----+-----+-----+-----+-----+-----+-----+-----+
Q W Y L R I D K R G K V K G T Q E M K N -
-AACTACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N Y N I M E I R T V A V G I V A I K G V -
-GAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGC-
+-----+-----+-----+-----+-----+-----+-----+-----+
E S E F Y L A M N K E G K L Y A K K E C -
-AACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCT
+-----+-----+-----+-----+-----+-----+-----+-----+
N E D C N F K E L I L E N H Y N T Y A S -
-GCTAAATGGACCCACAACGGTGGTGAAATGTTTCGTTGCTCTGAACCAGGAAGGTATCCCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
A K W T H N G G E M F V A L N Q E G I P -
-GTTTCGTGGTAAGAAAACCAAGAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATC-
+-----+-----+-----+-----+-----+-----+-----+-----+
V R G K K T K K E Q K T A H F L P M A I -
-ACTTAA-3'
+-----+
T *

Figure 42

 Δ N23/K(139)Q

5' -ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC-
+-----+-----+-----+-----+-----+-----+-----+-----+
M S Y D Y M E G G D I R V R R L F C R T -
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC-
+-----+-----+-----+-----+-----+-----+-----+-----+
Q W Y L R I D K R G K V K G T Q E M K N -
-AACTACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N Y N I M E I R T V A V G I V A I K G V -
-GAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGC-
+-----+-----+-----+-----+-----+-----+-----+-----+
E S E F Y L A M N K E G K L Y A K K E C -
-AACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N E D C N F K E L I L E N H Y N T Y A S -
-GCTAAATGGACCCACAACGGTGGTGAAATGTTTCGTTGCTCTGAACCAGCAAGGTATCCCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
A K W T H N G G E M F V A L N Q Q G I P -
-GTTTCGTGGTAAGAAAACCAAGAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATC-
+-----+-----+-----+-----+-----+-----+-----+-----+
V R G K K T K K E Q K T A H F L P M A I -
-ACTTAA-3'
+-----
T *

Figure 43

 Δ N23/R(144)A

5' -ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC-
+-----+-----+-----+-----+-----+-----+-----+-----+
M S Y D Y M E G G D I R V R R L F C R T -
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC-
+-----+-----+-----+-----+-----+-----+-----+-----+
Q W Y L R I D K R G K V K G T Q E M K N -
-AACTACAATATTATGGAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N Y N I M E I R T V A V G I V A I K G V -
-GAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGC-
+-----+-----+-----+-----+-----+-----+-----+-----+
E S E F Y L A M N K E G K L Y A K K E C -
-AACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N E D C N F K E L I L E N H Y N T Y A S -
-GCTAAATGGACCCACAACGGTGGTGAAATGTTTCGTTGCTCTGAACCAGAAAGGTATCCCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
A K W T H N G G E M F V A L N Q K G I P -
-GTTGCTGGTAAGAAAACCAAGAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATC-
+-----+-----+-----+-----+-----+-----+-----+-----+
V A G K K T K K E Q K T A H F L P M A I -
-ACTTAA-3'
+-----
T *

Figure 44

 Δ N23/R(144)E

5' -ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC-
+-----+-----+-----+-----+-----+-----+
M S Y D Y M E G G D I R V R R L F C R T -
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC-
+-----+-----+-----+-----+-----+-----+
Q W Y L R I D K R G K V K G T Q E M K N -
-AACTACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT-
+-----+-----+-----+-----+-----+-----+
N Y N I M E I R T V A V G I V A I K G V -
-GAATCTGAATTCTATCTTGCAATGAACAAGGAAGGAAAACCTCTATGCAAAGAAAGAATGC-
+-----+-----+-----+-----+-----+-----+
E S E F Y L A M N K E G K L Y A K K E C -
-AATGAAGATTGTAACCTCAAAGAACTAATTCTGGAAAACCATTACAACACATATGCATCT-
+-----+-----+-----+-----+-----+-----+
N E D C N F K F L I L E N H Y N T Y A S -
-GCTAAATGGACCCACAACGGTGGTGAAATGTTGCTGCTCTGAACCAGAAAGGTATCCCT-
+-----+-----+-----+-----+-----+-----+
A K W T H N G G E M F V A L N Q K G I P -
-GTTGAAGGTAAGAAAACCAAGAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATC-
+-----+-----+-----+-----+-----+-----+
V E G K K T K K E Q K T A H F L P M A I -
-ACTTAA-3'
+-----
T *

Figure 45

 Δ N23/R(144)L

5' -ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC-
+-----+-----+-----+-----+-----+-----+-----+-----+
M S Y D Y M E G G D I R V R R L F C R T -
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC-
+-----+-----+-----+-----+-----+-----+-----+-----+
Q W Y L R I D K R G K V K G T Q E M K N -
-AACTACAATATTATGGAAATCCGTACTGTTGCTFGTTGGTATCGTTGCAATCAAAGGTGTT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N Y N I M E I R T V A V G I V A I K G V -
-GAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGC-
+-----+-----+-----+-----+-----+-----+-----+-----+
E S E F Y L A M N K E G K L Y A K K E C -
-AACGAAGACTGCAACTTCAAAGAAGTATCCTGGAAAACCACTACAACACCTACGCATCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N E D C N F K E L I L E N H Y N T Y A S -
-GCTAAATGGACCCACAACGGTGGTGAAATGTTGCTTGCTCTGAACCAGAAAGGTATCCCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
A K W T H N G G E M F V A L N Q K G I P -
-GTTCTGGGTAAGAAAACCAAGAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATC-
+-----+-----+-----+-----+-----+-----+-----+-----+
V L G K K T K K E Q K T A H F L P M A I -
-ACTTAA-3'
+-----+
T *

Figure 46

 Δ N23/K(147)E

5' -ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC-
+-----+-----+-----+-----+-----+-----+-----+-----+
M S Y D Y M E G G D I R V R R L F C R T -
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC-
+-----+-----+-----+-----+-----+-----+-----+-----+
Q W Y L R I D K R G K V K G T Q E M K N -
-AACTACAATATTATGGAAATCCGTA CTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N Y N I M E I R T V A V G I V A I K G V -
-GAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGC-
+-----+-----+-----+-----+-----+-----+-----+-----+
E S E F Y L A M N K E G K L Y A K K E C -
-AACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N E D C N F K E L I L E N H Y N T Y A S -
-GCTAAATGGACCCACAACGGTGGTGAAATGTTGCTGCTCTGAACCAGAAAGGTATTCCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
A K W T H N G G E M F V A L N Q K G I P -
-GTTGCTGGTAAGGAAACCAAGAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATC-
+-----+-----+-----+-----+-----+-----+-----+-----+
V R G K E T K K E Q K T A H F L P M A I -
-ACTTAA-3'
+-----
T *

Figure 47

 Δ N23/K(147)Q

5' -ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC-
+-----+-----+-----+-----+-----+-----+-----+-----+
M S Y D Y M E G G D I R V R R L F C R T -
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC-
+-----+-----+-----+-----+-----+-----+-----+-----+
Q W Y L R I D K R G K V K G T Q E M K N -
-AACTACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N Y N I M E I R T V A V G I V A I K G V -
-GAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGC-
+-----+-----+-----+-----+-----+-----+-----+-----+
E S E F Y L A M N K E G K L Y A K K E C -
-AACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N E D C N F K E L I L E N H Y N T Y A S -
-GCTAAATGGACCCACAACGGTGGTGAAATGTTGCTTGCTCTGAACCAGAAAGGTATCCCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
A K W T H N G G E M F V A L N Q K G I P -
-GTTTCGTGGTAAGCAAACCAAGAAAGAACAGAAAACCGCTCACTTCCTGCCGATGGCAATC-
+-----+-----+-----+-----+-----+-----+-----+-----+
V R G K Q T K K E Q K T A H F L P M A I -
-ACTTAA-3'
+-----+
T *

Figure 48

 Δ N23/K(153)E

5' -ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC-
+-----+-----+-----+-----+-----+-----+-----+-----+
M S Y D Y M E G G D I R V R R L F C R T -
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC-
+-----+-----+-----+-----+-----+-----+-----+-----+
Q W Y L R I D K R G K V K G T Q E M K N -
-AACTACAATATTATGGAAATCCGTA CTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N Y N I M E I R T V A V G I V A I K G V -
-GAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGC-
+-----+-----+-----+-----+-----+-----+-----+-----+
E S E F Y L A M N K E G K L Y A K K E C -
-AACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N E D C N F K E L I L E N H Y N T Y A S
-GCTAAATGGACCCACAACGGTGGTGAAATGTTCTGTTGCTCTGAACCAGAAAGGTATCCCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
A K W T H N G G E M F V A L N Q K G I P -
-GTTCTGGTAAGAAAACCAAGAAAGAACAGGAAACCGCTCACTTCCTGCCGATGGCAATC-
+-----+-----+-----+-----+-----+-----+-----+-----+
V R G K K T K K E Q E T A H F L P M A I -
-ACTTAA-3'
+-----
T *

Figure 49

 Δ N23/K(153)Q


5' - ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC -
+-----+-----+-----+-----+-----+-----+-----+-----+
M S Y D Y M E G G D I R V R R L F C R T -
- CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC -
+-----+-----+-----+-----+-----+-----+-----+-----+
Q W Y L R I D K R G K V K G T Q E M K N -
- AACTACAATATTATGGAAATCCGTACTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT -
+-----+-----+-----+-----+-----+-----+-----+-----+
N Y N I M E I R T V A V G I V A I K G V -
- GAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGC -
+-----+-----+-----+-----+-----+-----+-----+-----+
E S E F Y L A M N K E G K L Y A K K E C -
- AACGAAGACTGCAACTTCAAAGAACTGATCCTGGAAAACCACTACAACACCTACGCATCT -
+-----+-----+-----+-----+-----+-----+-----+-----+
N E D C N F K E L I L E N H Y N T Y A S -
- GCTAAATGGACCCACAACGGTGGTGAAATGTTGCTTGCTCTGAACCAGAAAGGTATCCCT -
+-----+-----+-----+-----+-----+-----+-----+-----+
A K W T H N G G E M F V A L N Q K G I P -
- GTTCGTGGTAAGAAAACCAAGAAAGAACAGCAAACCGCTCACTTCCTGCCGATGGCAATC -
+-----+-----+-----+-----+-----+-----+-----+-----+
V R G K K T K K E Q Q T A H F L P M A I -
- ACTTAA-3'
+-----+
T * -


Figure 50

 Δ N23/Q(152)E/K(153)E

5' -ATGTCCTACGACTACATGGAAGGTGGTGACATCCGCGTACGTCGTCTGTTCTGCCGTACC-
+-----+-----+-----+-----+-----+-----+-----+-----+
M S Y D Y M E G G D I R V R R L F C R T -
-CAGTGGTACCTGCGTATCGACAAACGCGGCAAAGTCAAGGGCACCCAAGAGATGAAAAAC-
+-----+-----+-----+-----+-----+-----+-----+-----+
Q W Y L R I D K R G K V K G T Q E M K N -
-AACTACAATATTATGGAAATCCGTA CTGTTGCTGTTGGTATCGTTGCAATCAAAGGTGTT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N Y N I M E I R T V A V G I V A I K G V -
-GAATCTGAATTCTACCTGGCAATGAACAAAGAAGGTAAACTGTACGCAAAAAAAGAATGC-
+-----+-----+-----+-----+-----+-----+-----+-----+
E S E F Y L A M N K E G K L Y A K K E C -
-AACGAAGACTGCAACTTCAAAGA ACTGATCCTGGAAAACCACTACAACACCTACGCATCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
N F D C N F K E L I L E N H Y N T Y A S -
-GCTAAATGGACCCACAACGGTGGTGAAATGTTGCTGCTCTGAACCAGAAAGGTATCCCT-
+-----+-----+-----+-----+-----+-----+-----+-----+
A K W T H N G G E M F V A L N Q K G I P -
-GTTCGTGGTAAGAAAACCAAGAAAGAAGAGGAAACCGCTCACTTCCTGCCGATGGCAATC-
+-----+-----+-----+-----+-----+-----+-----+-----+
V R G K K T K K E E E T A H F L P M A I -
-ACTTAA-3'
+-----+
T *

FIGURE 51





PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/50, C12N 15/12, A61K 38/18		A3	(11) International Publication Number: WO 96/11949
			(43) International Publication Date: 25 April 1996 (25.04.96)
(21) International Application Number: PCT/IB95/00971		Suite 2105, 6400 Christie Avenue, Emeryville, CA 94608 (US). HSU, Eric, W. [US/US]; 2110 Mapleleaf Avenue, Thousand Oaks, CA 91320 (US).	
(22) International Filing Date: 12 October 1995 (12.10.95)		(74) Agents: ODRE, Steven, M. et al.; Amgen Inc., Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US).	
(30) Priority Data: 08/323,340 13 October 1994 (13.10.94) US 08/323,475 13 October 1994 (13.10.94) US 08/487,825 7 June 1995 (07.06.95) US		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(60) Parent Applications or Grants (63) Related by Continuation US 08/323,340 (CIP) Filed on 13 October 1994 (13.10.94) US 08/487,825 (CIP) Filed on 7 June 1995 (07.06.95)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): AMGEN INC. [US/US]; Amgen Center, 1840 Dehavilland Drive, Thousand Oaks, CA 91320-1789 (US).		(88) Date of publication of the international search report: 12 December 1996 (12.12.96)	
(72) Inventors; and (75) Inventors/Applicants (for US only): MORRIS, Charles, F. [US/US]; 3393 Daniel Street, Newbury Park, CA 91320 (US). KENNEY, William, C. [US/US]; 2654 Castillo Circle, Thousand Oaks, CA 91360 (US). CHEN, Bao-Lu [US/US];			
(54) Title: ANALOGS OF KERATINOCYTE GROWTH FACTOR			
(57) Abstract <p>The present invention concerns polypeptide analogs of a potent mitogen of non-fibroblast epithelial cell growth, keratinocyte growth factor (KGF) having up to the first 24 N-terminal amino acids modified wherein cysteine residues corresponding to amino acid positions 1 and 15 of the KGF [amino acid positions 32 and 46 of SEQ ID No:2, (Cys¹ and Cys¹⁵, respectively), are deleted or substituted with another amino acid. Also disclosed are nucleic acid molecules encoding such analogs, as well as methods for using such analogs to stimulate non-fibroblast epithelial cell proliferation.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 95/00971

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K14/50 C12N15/12 A61K38/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 4, 5 February 1993, MD US, pages 2984-2988, XP002008659 D. RON ET AL: "Expression of biologically active rKGF" cited in the application The whole document; see especially p. 2988, par.3	1-3,9
P,X	--- WO,A,95 01434 (CHIRON CORP) 12 January 1995 see the whole document --- -/--	1-3, 9-15, 21-28

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

28 October 1996

Date of mailing of the international search report

05. 11. 96

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tlx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Groenendijk, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 95/00971

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 205, no. 1, 30 November 1994, ORLANDO, FL US, pages 872-879, XP002008660 L.A.BARE ET AL: "Effect of cysteine substitutions on the mitogenic activity and stability of rKGF" see the whole document ---	1,6-13, 18-28
P,X	WO,A,95 03831 (PRIZM PHARMA INC ;WHITTIER INST FOR DIABETES AND (US)) 9 February 1995 see page 35 - page 38 ---	1,6-9, 13,18-27
A	WO,A,90 08771 (RUBIN JEFFREY S ;FINCH PAUL W (US); AARONSON STUART A (US)) 9 August 1990 cited in the application see the whole document ---	1-28
A	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 151, no. 2, 15 March 1988, ORLANDO, FL US, pages 701-708, XP002008661 N.SENO T AL: "Stabilizing bFGF using protein engineering" see the whole document ---	1-28
A	EP,A,0 510 662 (TAKEDA CHEMICAL INDUSTRIES LTD) 28 October 1992 see the whole document -----	1-28

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 95/00971

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 28
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although this claim as far as used in vivo is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 95/00971

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9501434	12-01-95	AU-A- 6820894	24-01-95
		BG-A- 100236	31-07-96
		BR-A- 9407035	12-03-96
		EP-A- 0706563	17-04-96
		FI-A- 956203	07-02-96
		HU-A- 73453	28-08-96
		NO-A- 955189	20-12-95
		PL-A- 312257	01-04-96

WO-A-9503831	09-02-95	AU-A- 7475694	28-02-95
		CA-A- 2168647	09-02-95
		EP-A- 0712314	22-05-96

WO-A-9008771	09-08-90	AU-B- 647732	31-03-94
		AU-A- 5049690	24-08-90
		AU-A- 6598694	08-09-94
		CA-A- 2038398	16-09-92
		EP-A- 0555205	18-08-93
		JP-T- 4504415	06-08-92
		KR-B- 9512805	21-10-95
		LT-A,B 667	31-01-95
		LV-B- 10284	20-04-95

EP-A-0510662	28-10-92	CA-A- 2066931	27-10-92
		JP-A- 5262798	12-10-93
